{ "version": "2.2", "instance": { "ngen-20251231x40fa.htm ngen-20251231xex99d2.htm": { "nsprefix": "ngen", "nsuri": "http://NervgenPharmaCorp.com/20251231", "dts": { "schema": { "local": [ "ngen-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd" ] }, "calculationLink": { "local": [ "ngen-20251231_cal.xml" ] }, "definitionLink": { "local": [ "ngen-20251231_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "ngen-20251231_lab.xml" ] }, "presentationLink": { "local": [ "ngen-20251231_pre.xml" ] }, "inline": { "local": [ "ngen-20251231x40fa.htm", "ngen-20251231xex99d2.htm" ] } }, "keyStandard": 202, "keyCustom": 99, "axisStandard": 18, "axisCustom": 3, "memberStandard": 24, "memberCustom": 52, "hidden": { "total": 11, "http://NervgenPharmaCorp.com/20251231": 6, "http://xbrl.sec.gov/dei/2025": 5 }, "contextCount": 191, "entityCount": 1, "segmentCount": 79, "elementCount": 498, "unitCount": 14, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 685, "http://xbrl.sec.gov/dei/2025": 45 }, "report": { "R1": { "role": "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231x40fa.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231x40fa.htm", "first": true, "unique": true } }, "R2": { "role": "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition", "longName": "00100 - Statement - Consolidated Statements of Financial Position", "shortName": "Consolidated Statements of Financial Position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_1_1_2024_pK01n-or_kyhBfBwiMZ4Xw", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R3": { "role": "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss", "longName": "00200 - Statement - Consolidated Statements of Loss and Comprehensive Loss", "shortName": "Consolidated Statements of Loss and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "00300 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:AdjustmentsForAmortisationExpense", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R5": { "role": "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity", "longName": "00400 - Statement - Consolidated Statements of Changes in Shareholders' Equity", "shortName": "Consolidated Statements of Changes in Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_r-Nknnb8_0-6uiFrJBRfqg", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_r-Nknnb8_0-6uiFrJBRfqg", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R6": { "role": "http://NervgenPharmaCorp.com/role/DisclosureNatureOfBusiness", "longName": "10101 - Disclosure - Nature of business", "shortName": "Nature of business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:DisclosureOfNatureOfOperationsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:DisclosureOfNatureOfOperationsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R7": { "role": "http://NervgenPharmaCorp.com/role/DisclosureBasisOfPresentation", "longName": "10201 - Disclosure - Basis of presentation", "shortName": "Basis of presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R8": { "role": "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPolicies", "longName": "10301 - Disclosure - Material accounting policies", "shortName": "Material accounting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R9": { "role": "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatements", "longName": "10401 - Disclosure - Restatement of Prior Period Financial Statements", "shortName": "Restatement of Prior Period Financial Statements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:IfrsErrorCorrectionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:IfrsErrorCorrectionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R10": { "role": "http://NervgenPharmaCorp.com/role/DisclosureUseOfJudgementsAndEstimates", "longName": "10501 - Disclosure - Use of judgements and estimates", "shortName": "Use of judgements and estimates", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R11": { "role": "http://NervgenPharmaCorp.com/role/DisclosureSegmentReporting", "longName": "10601 - Disclosure - Segment reporting", "shortName": "Segment reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R12": { "role": "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosures", "longName": "10701 - Disclosure - Capital disclosures", "shortName": "Capital disclosures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R13": { "role": "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagement", "longName": "10801 - Disclosure - Financial risk management", "shortName": "Financial risk management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R14": { "role": "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssets", "longName": "10901 - Disclosure - Prepaids, deposits, and other current assets", "shortName": "Prepaids, deposits, and other current assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R15": { "role": "http://NervgenPharmaCorp.com/role/DisclosureReceivables", "longName": "11001 - Disclosure - Receivables", "shortName": "Receivables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R16": { "role": "http://NervgenPharmaCorp.com/role/DisclosurePropertyAndEquipment", "longName": "11101 - Disclosure - Property and equipment", "shortName": "Property and equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R17": { "role": "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiability", "longName": "11201 - Disclosure - Net investment in lease and lease liability", "shortName": "Net investment in lease and lease liability", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R18": { "role": "http://NervgenPharmaCorp.com/role/DisclosureIntangibleAsset", "longName": "11301 - Disclosure - Intangible asset", "shortName": "Intangible asset", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R19": { "role": "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilities", "longName": "11401 - Disclosure - Accounts payable and accrued liabilities", "shortName": "Accounts payable and accrued liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R20": { "role": "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnel", "longName": "11501 - Disclosure - Key management personnel", "shortName": "Key management personnel", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R21": { "role": "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivative", "longName": "11601 - Disclosure - Warrant derivative", "shortName": "Warrant derivative", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R22": { "role": "http://NervgenPharmaCorp.com/role/DisclosureShareCapital", "longName": "11701 - Disclosure - Share capital", "shortName": "Share capital", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R23": { "role": "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrants", "longName": "11801 - Disclosure - Stock options, retention securities and warrants", "shortName": "Stock options, retention securities and warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R24": { "role": "http://NervgenPharmaCorp.com/role/DisclosureCommitments", "longName": "11901 - Disclosure - Commitments", "shortName": "Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R25": { "role": "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpenses", "longName": "12001 - Disclosure - Nature of expenses", "shortName": "Nature of expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R26": { "role": "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxes", "longName": "12101 - Disclosure - Income taxes", "shortName": "Income taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R27": { "role": "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEvents", "longName": "12201 - Disclosure - Subsequent events", "shortName": "Subsequent events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R28": { "role": "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPolicies", "longName": "20302 - Disclosure - Material accounting policies (Policies)", "shortName": "Material accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R29": { "role": "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesTables", "longName": "30303 - Disclosure - Material accounting policies (Tables)", "shortName": "Material accounting policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:DisclosureOfUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:DisclosureOfUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R30": { "role": "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsTables", "longName": "30403 - Disclosure - Restatement of Prior Period Financial Statements (Tables)", "shortName": "Restatement of Prior Period Financial Statements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:IfrsScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:IfrsScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R31": { "role": "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementTables", "longName": "30803 - Disclosure - Financial risk management (Tables)", "shortName": "Financial risk management (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfMarketRiskExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfMarketRiskExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R32": { "role": "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsTables", "longName": "30903 - Disclosure - Prepaids, deposits, and other current assets (Tables)", "shortName": "Prepaids, deposits, and other current assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:DisclosureOfPrepaymentsDepositsAndOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:DisclosureOfPrepaymentsDepositsAndOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R33": { "role": "http://NervgenPharmaCorp.com/role/DisclosureReceivablesTables", "longName": "31003 - Disclosure - Receivables (Tables)", "shortName": "Receivables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:DisclosureOfReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:DisclosureOfReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R34": { "role": "http://NervgenPharmaCorp.com/role/DisclosurePropertyAndEquipmentTables", "longName": "31103 - Disclosure - Property and equipment (Tables)", "shortName": "Property and equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R35": { "role": "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityTables", "longName": "31203 - Disclosure - Net investment in lease and lease liability (Tables)", "shortName": "Net investment in lease and lease liability (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:DisclosureOfDetailedInformationAboutLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:DisclosureOfDetailedInformationAboutLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R36": { "role": "http://NervgenPharmaCorp.com/role/DisclosureIntangibleAssetTables", "longName": "31303 - Disclosure - Intangible asset (Tables)", "shortName": "Intangible asset (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R37": { "role": "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables", "longName": "31403 - Disclosure - Accounts payable and accrued liabilities (Tables)", "shortName": "Accounts payable and accrued liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:ScheduleOfTradeAndOtherCurrentPayablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:ScheduleOfTradeAndOtherCurrentPayablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R38": { "role": "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelTables", "longName": "31503 - Disclosure - Key management personnel (Tables)", "shortName": "Key management personnel (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R39": { "role": "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeTables", "longName": "31603 - Disclosure - Warrant derivative (Tables)", "shortName": "Warrant derivative (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R40": { "role": "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalTables", "longName": "31703 - Disclosure - Share capital (Tables)", "shortName": "Share capital (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R41": { "role": "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsTables", "longName": "31803 - Disclosure - Stock options, retention securities and warrants (Tables)", "shortName": "Stock options, retention securities and warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R42": { "role": "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpenseTables", "longName": "32003 - Disclosure - Nature of expense (Tables)", "shortName": "Nature of expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R43": { "role": "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTables", "longName": "32103 - Disclosure - Income taxes (Tables)", "shortName": "Income taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R44": { "role": "http://NervgenPharmaCorp.com/role/DisclosureNatureOfBusinessDetails", "longName": "40101 - Disclosure - Nature of business (Details)", "shortName": "Nature of business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:NumberOfWhollyOwnedSubsidiaries", "unitRef": "Unit_Standard_subsidiary_KgmGLWUyoU2yamFMlNW9Fw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ngen:DisclosureOfNatureOfOperationsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:NumberOfWhollyOwnedSubsidiaries", "unitRef": "Unit_Standard_subsidiary_KgmGLWUyoU2yamFMlNW9Fw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ngen:DisclosureOfNatureOfOperationsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R45": { "role": "http://NervgenPharmaCorp.com/role/DisclosureBasisOfPresentationDetails", "longName": "40201 - Disclosure - Basis of presentation (Details)", "shortName": "Basis of presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:ProceedsFromIssuingShares", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_5_1_2026_To_5_31_2026_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ngen_PublicOfferingMember_mnogZ2wkvUu8CfEf5v4rCw", "name": "ifrs-full:ProceedsFromIssuingShares", "unitRef": "Unit_Standard_USD_6c_6BnBK40WUIxuzryldkg", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R46": { "role": "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPropertyAndEquipmentDetails", "longName": "40301 - Disclosure - Material accounting policies - Property and equipment (Details)", "shortName": "Material accounting policies - Property and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:NumberOfCashGeneratingUnitsForImpairmentTesting", "unitRef": "Unit_Standard_item_moAy4RLWXEqk2FjKigpQJg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:NumberOfCashGeneratingUnitsForImpairmentTesting", "unitRef": "Unit_Standard_item_moAy4RLWXEqk2FjKigpQJg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R47": { "role": "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesStockBasedCompensationAndRetentionSecuritiesDetails", "longName": "40302 - Disclosure - Material accounting policies - Stock-based compensation and retention securities (Details)", "shortName": "Material accounting policies - Stock-based compensation and retention securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R48": { "role": "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesFinancialInstrumentsDetails", "longName": "40303 - Disclosure - Material accounting policies - Financial instruments (Details)", "shortName": "Material accounting policies - Financial instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R49": { "role": "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "longName": "40401 - Disclosure - Restatement of Prior Period Financial Statements - Consolidated Statements of Financial Position (Details)", "shortName": "Restatement of Prior Period Financial Statements - Consolidated Statements of Financial Position (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ifrs-full:TradeAndOtherCurrentPayables", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_8dwZhTRGEEubDFsr2ZGEmA", "name": "ifrs-full:TradeAndOtherCurrentPayables", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ngen:IfrsScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R50": { "role": "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails", "longName": "40402 - Disclosure - Restatement of Prior Period Financial Statements - Consolidated Statements of Loss and Comprehensive Loss (Details)", "shortName": "Restatement of Prior Period Financial Statements - Consolidated Statements of Loss and Comprehensive Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_XCyJbuJ76EajrVEaAZXrmQ", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R51": { "role": "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfCashFlowsDetails", "longName": "40403 - Disclosure - Restatement of Prior Period Financial Statements - Consolidated Statements of Cash Flows (Details)", "shortName": "Restatement of Prior Period Financial Statements - Consolidated Statements of Cash Flows (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:OtherAdjustmentsForNoncashItems", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R52": { "role": "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "longName": "40404 - Disclosure - Restatement of Prior Period Financial Statements - Consolidated Statements of Changes in Shareholders' Equity (Details)", "shortName": "Restatement of Prior Period Financial Statements - Consolidated Statements of Changes in Shareholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_12_31_2024_a-g_9dlzKU6_Z1aiyaOyRw", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_XCyJbuJ76EajrVEaAZXrmQ", "name": "ifrs-full:IssueOfEquity", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R53": { "role": "http://NervgenPharmaCorp.com/role/DisclosureSegmentReportingDetails", "longName": "40601 - Disclosure - Segment reporting (Details)", "shortName": "Segment reporting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:IfrsNumberOfReportableSegments", "unitRef": "Unit_Standard_segment_BS6B6bmFzk2ACtMjnxTKEg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "ngen:IfrsNumberOfOperatingSegments", "p", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:IfrsNumberOfReportableSegments", "unitRef": "Unit_Standard_segment_BS6B6bmFzk2ACtMjnxTKEg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "ngen:IfrsNumberOfOperatingSegments", "p", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R54": { "role": "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosuresDetails", "longName": "40701 - Disclosure - Capital disclosures (Details)", "shortName": "Capital disclosures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "As_Of_12_15_2025_uHitZpOke0GBR4J44-p3JQ", "name": "ngen:BaseShelfProspectusOfferingOfSecuritiesAuthorisedAmount", "unitRef": "Unit_Standard_USD_6c_6BnBK40WUIxuzryldkg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_19_2024_ngen_IfrsSaleOfStockAxis_ngen_AttheMarketProgramMember_9Isbm4aQ90GDMBPD7nS1zA", "name": "ngen:MaximumSharesSaleableAmount", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R55": { "role": "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementDetails", "longName": "40801 - Disclosure - Financial risk management (Details)", "shortName": "Financial risk management (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_DerivativesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_2D1ua3OYzUaN4HvTc95XkA", "name": "ifrs-full:FinancialLiabilitiesAtFairValue", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_DerivativesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_2D1ua3OYzUaN4HvTc95XkA", "name": "ifrs-full:FinancialLiabilitiesAtFairValue", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R56": { "role": "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementCurrencyRiskDetails", "longName": "40802 - Disclosure - Financial risk management - Currency risk (Details)", "shortName": "Financial risk management - Currency risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_8K1AV9plBEKcy8gzCnQ9xw", "name": "ngen:PercentageOfReasonablyPossibleChangeInRiskVariable", "unitRef": "Unit_Standard_pure_FYa9vnDgq0G4ARfz5ZV-Wg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_8K1AV9plBEKcy8gzCnQ9xw", "name": "ngen:PercentageOfReasonablyPossibleChangeInRiskVariable", "unitRef": "Unit_Standard_pure_FYa9vnDgq0G4ARfz5ZV-Wg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R57": { "role": "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails", "longName": "40803 - Disclosure - Financial risk management - Schedule of currency risk (Details)", "shortName": "Financial risk management - Schedule of currency risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ifrs-full:TradeAndOtherCurrentReceivables", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_jsoVCnYRQU60uMOuoP74vw", "name": "ifrs-full:Cash", "unitRef": "Unit_Standard_USD_6c_6BnBK40WUIxuzryldkg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfMarketRiskExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R58": { "role": "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails", "longName": "40901 - Disclosure - Prepaids, deposits, and other current assets (Details)", "shortName": "Prepaids, deposits, and other current assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ngen:IfrsPrepaidInsurance", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ngen:DisclosureOfPrepaymentsDepositsAndOtherCurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ngen:IfrsPrepaidInsurance", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ngen:DisclosureOfPrepaymentsDepositsAndOtherCurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R59": { "role": "http://NervgenPharmaCorp.com/role/DisclosureReceivablesDetails", "longName": "41001 - Disclosure - Receivables (Details)", "shortName": "Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ngen:DisclosureOfReceivablesTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ngen:DisclosureOfReceivablesTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R60": { "role": "http://NervgenPharmaCorp.com/role/DisclosurePropertyAndEquipmentDetails", "longName": "41101 - Disclosure - Property and equipment (Details)", "shortName": "Property and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "As_Of_12_31_2023_IlLa4GOFUEan-lQkEVRqTg", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_IlLa4GOFUEan-lQkEVRqTg", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R61": { "role": "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails", "longName": "41201 - Disclosure - Net investment in lease and lease liability - Changes in carrying amounts (Details)", "shortName": "Net investment in lease and lease liability - Changes in carrying amounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_12_31_2023_IlLa4GOFUEan-lQkEVRqTg", "name": "ifrs-full:RightofuseAssets", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ngen:DisclosureOfDetailedInformationAboutLeasesTableTextBlock", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_IlLa4GOFUEan-lQkEVRqTg", "name": "ifrs-full:RightofuseAssets", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ngen:DisclosureOfDetailedInformationAboutLeasesTableTextBlock", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R62": { "role": "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityDetails", "longName": "41202 - Disclosure - Net investment in lease and lease liability (Details)", "shortName": "Net investment in lease and lease liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_CGU59tAbxES1qCRqsB1fhA", "name": "ifrs-full:DisposalsAndRetirementsRightofuseAssets", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:NetInvestmentInFinanceLeaseRentExpense", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R63": { "role": "http://NervgenPharmaCorp.com/role/DisclosureIntangibleAssetDetails", "longName": "41301 - Disclosure - Intangible asset (Details)", "shortName": "Intangible asset (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_IlLa4GOFUEan-lQkEVRqTg", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R64": { "role": "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails", "longName": "41401 - Disclosure - Accounts payable and accrued liabilities (Details)", "shortName": "Accounts payable and accrued liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ngen:ScheduleOfTradeAndOtherCurrentPayablesTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ngen:ScheduleOfTradeAndOtherCurrentPayablesTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R65": { "role": "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelDetails", "longName": "41501 - Disclosure - Key management personnel (Details)", "shortName": "Key management personnel (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R66": { "role": "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "longName": "41502 - Disclosure - Key management personnel - Additional information (Details)", "shortName": "Key management personnel - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ngen:KeyManagementPersonnelShortTermEmployeeBenefitsAccrualsCurrent", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ngen:KeyManagementPersonnelShortTermEmployeeBenefitsAccrualsCurrent", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R67": { "role": "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails", "longName": "41601 - Disclosure - Warrant derivative (Details)", "shortName": "Warrant derivative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "Duration_11_19_2025_To_11_19_2025_goaW_BqNtkiovFGhwca3pQ", "name": "ngen:UnitsIssuedDuringPeriodUnitsNewIssues", "unitRef": "Unit_Standard_shares_qGIKvhVLNE-B1fkYRqf3zw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_7_13_2022_ifrs-full_ClassesOfLiabilitiesAxis_ngen_July2022WarrantsMember_3y00KWXIkUic8VAJzhS4XA", "name": "ngen:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "unitRef": "Unit_Standard_shares_qGIKvhVLNE-B1fkYRqf3zw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R68": { "role": "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails", "longName": "41602 - Disclosure - Warrant derivative - Schedule of Reconciliation of the change in fair value of warrant derivatives (Details)", "shortName": "Warrant derivative - Schedule of Reconciliation of the change in fair value of warrant derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "As_Of_12_31_2024_a-g_9dlzKU6_Z1aiyaOyRw", "name": "ifrs-full:Liabilities", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_ClassesOfLiabilitiesAxis_ngen_July2022WarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_vsgwz92vpkKmUz9nIrO_DQ", "name": "ifrs-full:Liabilities", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R69": { "role": "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails", "longName": "41603 - Disclosure - Warrant derivative - Schedule of assumption for estimated fair value of the warrant derivatives (Details)", "shortName": "Warrant derivative - Schedule of assumption for estimated fair value of the warrant derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ngen:IfrsClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_qGIKvhVLNE-B1fkYRqf3zw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_ClassesOfLiabilitiesAxis_ifrs-full_DerivativesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_MFJACqAuS0iV5ebcHXkJpQ", "name": "ngen:IfrsClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_qGIKvhVLNE-B1fkYRqf3zw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ngen:DisclosureOfSignificantObservableInputsUsedInFairValueMeasurementOfLiabilitiesTableTextBlock", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R70": { "role": "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "longName": "41701 - Disclosure - Share capital (Details)", "shortName": "Share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:IncreaseInNumberOfSharesOutstandingOptionExercises", "unitRef": "Unit_Standard_shares_qGIKvhVLNE-B1fkYRqf3zw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ngen:StockProceedsAllocatedToLiabilityComponent", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R71": { "role": "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalScheduleOfNumberOfSharesOutstandingAndWeightedAverageNumberOfSharesDetails", "longName": "41702 - Disclosure - Share capital - Schedule of number of shares outstanding and weighted average number of shares (Details)", "shortName": "Share capital - Schedule of number of shares outstanding and weighted average number of shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "As_Of_12_31_2024_a-g_9dlzKU6_Z1aiyaOyRw", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "Unit_Standard_shares_qGIKvhVLNE-B1fkYRqf3zw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding", "unitRef": "Unit_Standard_shares_qGIKvhVLNE-B1fkYRqf3zw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R72": { "role": "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsTransactionsDetails", "longName": "41801 - Disclosure - Stock options, retention securities and warrants - Stock options transactions (Details)", "shortName": "Stock options, retention securities and warrants - Stock options transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "As_Of_12_31_2024_a-g_9dlzKU6_Z1aiyaOyRw", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Unit_Standard_Options_W8RG-Q0pbUmcLgqgVN12CA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_Options_W8RG-Q0pbUmcLgqgVN12CA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R73": { "role": "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails", "longName": "41802 - Disclosure - Stock options, retention securities and warrants - Stock options (Details)", "shortName": "Stock options, retention securities and warrants - Stock options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Unit_Standard_Options_W8RG-Q0pbUmcLgqgVN12CA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R74": { "role": "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsFairValueOfOptionsGrantedDetails", "longName": "41803 - Disclosure - Stock options, retention securities and warrants - Fair value of options granted (Details)", "shortName": "Stock options, retention securities and warrants - Fair value of options granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_39Rs7Y4kJ0Oqc-mtgR3x8Q", "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted", "unitRef": "Unit_Standard_pure_FYa9vnDgq0G4ARfz5ZV-Wg", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_39Rs7Y4kJ0Oqc-mtgR3x8Q", "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted", "unitRef": "Unit_Standard_pure_FYa9vnDgq0G4ARfz5ZV-Wg", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R75": { "role": "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsNarrativesDetails", "longName": "41804 - Disclosure - Stock options, retention securities and warrants - Narratives (Details)", "shortName": "Stock options, retention securities and warrants - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ngen_RetentionSecuritiesMember_Xh3mjN9C9kyokFBT1BVMzg", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "Unit_Standard_security_UGr1B7Nw5U2C2aW02lpoug", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ngen_RetentionSecuritiesMember_Xh3mjN9C9kyokFBT1BVMzg", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "Unit_Standard_security_UGr1B7Nw5U2C2aW02lpoug", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R76": { "role": "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails", "longName": "41805 - Disclosure - Stock options, retention securities and warrants - Warrants (Details)", "shortName": "Stock options, retention securities and warrants - Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "As_Of_12_31_2024_a-g_9dlzKU6_Z1aiyaOyRw", "name": "ngen:IfrsClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_qGIKvhVLNE-B1fkYRqf3zw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_IlLa4GOFUEan-lQkEVRqTg", "name": "ngen:ExercisePriceOfWarrantsOutstanding", "unitRef": "Unit_Divide_USD_shares_QIK3QSTh4UmB3Ik6FgG5MQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R77": { "role": "http://NervgenPharmaCorp.com/role/DisclosureCommitmentDetails", "longName": "41901 - Disclosure - Commitment (Details)", "shortName": "Commitment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "Duration_6_1_2023_To_6_30_2023_pTKMEgjn8U6P7CfTszziOQ", "name": "ifrs-full:ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities", "unitRef": "Unit_Standard_USD_6c_6BnBK40WUIxuzryldkg", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "p", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2023_To_6_30_2023_pTKMEgjn8U6P7CfTszziOQ", "name": "ifrs-full:ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities", "unitRef": "Unit_Standard_USD_6c_6BnBK40WUIxuzryldkg", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "p", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R78": { "role": "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesResearchAndDevelopmentExpenseDetails", "longName": "42001 - Disclosure - Nature of expenses - Research and Development Expense (Details)", "shortName": "Nature of expenses - Research and Development Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_ngen_AmortizationOfIntangibleAssetsMember_8CeGtgOcQkKLhYH-aruOcA", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R79": { "role": "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesGeneralAndAdministrationExpenseDetails", "longName": "42002 - Disclosure - Nature of expenses - General and Administration Expense (Details)", "shortName": "Nature of expenses - General and Administration Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:GeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_ngen_DepreciationExpenseMember_cbdLAIAuZEG9CX3TKc-Feg", "name": "ifrs-full:GeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } }, "R80": { "role": "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails", "longName": "42101 - Disclosure - Income taxes - Reconciliation of income taxes at statutory rates with the reported taxes (Details)", "shortName": "Income taxes - Reconciliation of income taxes at statutory rates with the reported taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:AccountingProfit", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ngen:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:AccountingProfit", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ngen:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R81": { "role": "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails", "longName": "42102 - Disclosure - Income taxes - Deferred income tax (Details)", "shortName": "Income taxes - Deferred income tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ZWevKng59028MlE3lTrrtQ", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R82": { "role": "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails", "longName": "42103 - Disclosure - Income taxes - Temporary differences, unused tax credits and unused tax losses not included in statements of financial position (Details)", "shortName": "Income taxes - Temporary differences, unused tax credits and unused tax losses not included in statements of financial position (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_GeographicalAreasAxis_country_CA_fPIYA1LYCUCzG2OU483UMg", "name": "ngen:DeductibleTemporaryDifferencesUnusedTaxCreditsUnusedTaxLossesForWhichNoDeferredTaxAssetIsRecognized", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_GeographicalAreasAxis_country_CA_fPIYA1LYCUCzG2OU483UMg", "name": "ngen:DeductibleTemporaryDifferencesUnusedTaxCreditsUnusedTaxLossesForWhichNoDeferredTaxAssetIsRecognized", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true, "unique": true } }, "R83": { "role": "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails", "longName": "42201 - Disclosure - Subsequent events (Details)", "shortName": "Subsequent events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_bJQfhyGQ-kq8NiPz3zuIKw", "name": "ifrs-full:ProceedsFromExerciseOfOptions", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_1_1_2026_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_MajorOrdinaryShareTransactionsMember_ehpb1Ydo70ielgz9pvZKuQ", "name": "ifrs-full:ProceedsFromExerciseOfOptions", "unitRef": "Unit_Standard_CAD_7lNcKY1jL0ukzbEDTAws5w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ngen-20251231xex99d2.htm", "unique": true } } }, "tag": { "country_AU": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "AU", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/DisclosureSegmentReportingDetails" ], "lang": { "en-us": { "role": { "label": "AUSTRALIA", "terseLabel": "Australia" } } }, "auth_ref": [] }, "currency_AUD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "AUD", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "label": "Australia, Dollars", "terseLabel": "Australian dollar" } } }, "auth_ref": [] }, "ifrs-full_AccountingProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccountingProfit", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Accounting profit", "terseLabel": "Loss for the year" } }, "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r3", "r4", "r134", "r135" ] }, "ngen_AccruedLegalAndProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "AccruedLegalAndProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of current legal and professional fees payable.", "label": "Accrued Legal And Professional Fees, Current", "terseLabel": "Legal and professional fees" } } }, "auth_ref": [] }, "ngen_AccruedResearchAndDevelopmentExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "AccruedResearchAndDevelopmentExpenseCurrent", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accrued research and development expense due and payable within one year or normal operating cycle if longer.", "label": "Accrued Research And Development Expense, Current", "terseLabel": "Research and development" } } }, "auth_ref": [] }, "ngen_AdditionsToNetInvestmentInFinanceLease": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "AdditionsToNetInvestmentInFinanceLease", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails", "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "The amounts of additions to net investment in finance lease.", "label": "Additions To Net Investment In Finance Lease", "terseLabel": "Sublease", "verboseLabel": "Recognition of net investment in sublease" } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AddressTypeDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalScheduleOfNumberOfSharesOutstandingAndWeightedAverageNumberOfSharesDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "terseLabel": "Weighted average Common Shares outstanding, Diluted (in shares) (Note 17)" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r28" ] }, "ifrs-full_AdjustmentsForAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForAmortisationExpense", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for amortisation expense", "terseLabel": "Amortization of intangible asset (Note 13)" } } }, "auth_ref": [ "r250" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in prepaid expenses", "terseLabel": "Prepaid expenses (Note 9, 17)" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } } }, "auth_ref": [ "r250" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "Receivables (Note 10)" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r250" ] }, "ifrs-full_AdjustmentsForDepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationExpense", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for depreciation expense", "terseLabel": "Depreciation expense (Note 11, 12)" } }, "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r250" ] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfCashFlowsDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for fair value losses (gains)", "terseLabel": "Change in fair value of warrant derivative (Note 16)" } } }, "auth_ref": [ "r249" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "terseLabel": "Accounts payable and accrued liabilities (Note 14, 15)" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r250" ] }, "ifrs-full_AdjustmentsForInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForInterestExpense", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for interest expense", "terseLabel": "Interest expense on lease liability (Note 12)" } } }, "auth_ref": [ "r250" ] }, "ifrs-full_AdjustmentsForInterestIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForInterestIncome", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for interest income", "negatedLabel": "Interest income on net investment in lease (Note 12)" } } }, "auth_ref": [ "r250" ] }, "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for losses (gains) on disposal of non-current assets", "terseLabel": "Loss on derecognition of equipment (Note 11)" } } }, "auth_ref": [ "r247" ] }, "ngen_AdjustmentsForNetInvestmentInSubLease": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "AdjustmentsForNetInvestmentInSubLease", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for net investment in leases to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Net Investment In Sub Lease", "terseLabel": "Net investment in sub-sublease (Note 12)" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Items not involving cash:" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfCashFlowsDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Stock-based compensation (Note 15, 18)" } } }, "auth_ref": [ "r249" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for unrealised foreign exchange losses (gains)", "terseLabel": "Unrealized foreign exchange" } } }, "auth_ref": [ "r214", "r249" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "AllCurrenciesDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentDescription", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIntangibleAssetDetails" ], "lang": { "en-us": { "role": { "label": "Amortisation, intangible assets other than goodwill", "negatedLabel": "Amortization expense" } } }, "auth_ref": [ "r32", "r153" ] }, "ngen_AmortizationOfIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "AmortizationOfIntangibleAssetsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesResearchAndDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to amortization of intangible asset.", "label": "Amortization of Intangible Assets [Member]", "terseLabel": "Amortization of intangible asset" } } }, "auth_ref": [] }, "ngen_AnnualBaseSalary": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "AnnualBaseSalary", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of annual base salary.", "label": "Annual Base Salary", "terseLabel": "Annual base salary" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AnnualInformationForm", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r238" ] }, "ngen_AppointmentOfChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "AppointmentOfChiefFinancialOfficerMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for appointment of Chief Financial Officer.", "label": "Appointment of Chief Financial Officer [Member]", "terseLabel": "Appointment of Chief Financial Officer" } } }, "auth_ref": [] }, "ngen_AppointmentOfPresidentAndChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "AppointmentOfPresidentAndChiefExecutiveOfficerMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for appointment of President and Chief Executive Officer.", "label": "Appointment of President and Chief Executive Officer [Member]", "terseLabel": "Appointment of President and Chief Executive Officer" } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r62", "r63", "r66", "r109", "r111", "r172", "r173", "r197" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "ifrs-full_AtFairValueMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AtFairValueMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "At fair value [member]", "terseLabel": "At Fair value" } }, "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } } }, "auth_ref": [ "r37", "r38", "r54", "r62", "r157", "r171", "r172" ] }, "ngen_AtMarketProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "AtMarketProgramMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for At-The-Market Program.", "label": "At The Market program [Member]", "terseLabel": "At the market program" } } }, "auth_ref": [] }, "ngen_AttheMarketProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "AttheMarketProgramMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosuresDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for At-The-Market Program.", "label": "AtThe Market Program [Member]", "terseLabel": "ATM Program" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesGeneralAndAdministrationExpenseDetails", "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesResearchAndDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [axis]" } } }, "auth_ref": [ "r255", "r257" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesGeneralAndAdministrationExpenseDetails", "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesResearchAndDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [domain]" } } }, "auth_ref": [ "r255", "r257" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r238" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r236", "r237", "r238" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r236", "r237", "r238" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r236", "r237", "r238" ] }, "ngen_BaseShelfProspectusOfferingOfSecuritiesAuthorisedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "BaseShelfProspectusOfferingOfSecuritiesAuthorisedAmount", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosuresDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum aggregate offering amount of securities that the entity is authorized to issue under the Base Shelf prospectus.", "label": "Base Shelf Prospectus, Offering Of Securities, Authorised Amount", "terseLabel": "Authorised shelf offering amount" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic net loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r26", "r27" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsFairValueOfOptionsGrantedDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Bottom of range [member]", "terseLabel": "Minimum" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r42", "r68", "r78", "r93", "r124", "r218", "r220", "r253" ] }, "ngen_BritishColumbiaScientificResearchExperimentalDevelopmentInvestmentTaxCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "BritishColumbiaScientificResearchExperimentalDevelopmentInvestmentTaxCreditMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits attributable to British Columbia Scientific Research & Experimental Development Investment Tax Credit.", "label": "British Columbia Scientific Research & Experimental Development Investment Tax Credit [Member]", "terseLabel": "BC SRED ITC" } } }, "auth_ref": [] }, "ngen_BrokerWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "BrokerWarrantsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to broker warrants.", "label": "Broker Warrants [Member]", "terseLabel": "Broker warrants" } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "BusinessContactMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "terseLabel": "Business Contact", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r237", "r238" ] }, "country_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "CA", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails" ], "lang": { "en-us": { "role": { "label": "CANADA", "terseLabel": "Canada" } } }, "auth_ref": [] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails": { "parentTag": "ifrs-full_CurrentAssetsLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "label": "Cash", "terseLabel": "Cash" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r251" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "terseLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r43", "r60", "r125", "r194" ] }, "ngen_CashCommissionPaidToUnderwriter": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "CashCommissionPaidToUnderwriter", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash paid as commission to underwriters.", "label": "Cash Commission Paid To underwriter", "terseLabel": "Cash commission paid to underwriter" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Cash flows from financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r39", "r45" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Cash flows from investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r39", "r45" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Investing Activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfCashFlowsDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Cash flows from operating activities" } } }, "auth_ref": [ "r39", "r45" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Operating Activities" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r23", "r148" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r23", "r148" ] }, "ngen_ChemistryManufacturingAndControlsMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ChemistryManufacturingAndControlsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesResearchAndDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to chemistry, manufacturing and controls.", "label": "Chemistry, Manufacturing and Controls [Member]", "terseLabel": "Chemistry, manufacturing and controls" } } }, "auth_ref": [] }, "ngen_ChiefMedicalAdvisorMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ChiefMedicalAdvisorMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Chief Medical Advisor.", "label": "Chief Medical Advisor [Member]", "terseLabel": "Chief Medical Advisor" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r103", "r104", "r115", "r116" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r103", "r104", "r115", "r116" ] }, "ifrs-full_ClassesOfLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r67", "r175" ] }, "ifrs-full_ClassesOfLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } } }, "auth_ref": [ "r67", "r175" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r13", "r143" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r13", "r143" ] }, "ngen_ClinicalAndRegulatoryExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ClinicalAndRegulatoryExpenseMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesResearchAndDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to clinical and regulatory expense.", "label": "Clinical and Regulatory Expense [Member]", "terseLabel": "Clinical and regulatory" } } }, "auth_ref": [] }, "ngen_ClinicalTrialDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ClinicalTrialDeposits", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails": { "parentTag": "ngen_PrepaymentsDepositsAndOtherCurrentAssets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of clinical trial deposits.", "label": "Clinical Trial Deposits", "terseLabel": "Phase 1b/2a clinical trial deposit" } } }, "auth_ref": [] }, "ngen_CommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "CommitmentsAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Commitments" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r186" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r186" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Comprehensive loss" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r51", "r53", "r59", "r150", "r159", "r182", "r207", "r215" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer equipment [member]", "terseLabel": "Computer equipment" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r244" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelName", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CurrencyAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrencyRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrencyRiskMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementCurrencyRiskDetails", "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "label": "Currency risk [member]", "terseLabel": "Currency risk" } }, "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r79", "r80", "r81", "r82", "r107" ] }, "ifrs-full_CurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAdvancesToSuppliers", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails": { "parentTag": "ifrs-full_CurrentAssetsLiabilities", "weight": 1.0, "order": 2.0 }, "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails": { "parentTag": "ngen_PrepaymentsDepositsAndOtherCurrentAssets", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails", "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Current advances to suppliers", "terseLabel": "Vendor deposits" } }, "en": { "role": { "documentation": "The amount of current advances made to suppliers before goods or services are received." } } }, "auth_ref": [ "r257" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets", "totalLabel": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r55", "r199", "r215" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "ifrs-full_CurrentAssetsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsLiabilities", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "label": "Current assets (liabilities)", "totalLabel": "Total" } }, "en": { "role": { "documentation": "The amount of current assets less the amount of current liabilities." } } }, "auth_ref": [ "r260" ] }, "ifrs-full_CurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current derivative financial liabilities", "terseLabel": "Warrant derivative (Note 16)" } }, "en": { "role": { "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r260" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current lease liabilities", "terseLabel": "Current portion of lease liability (Note 12)", "verboseLabel": "Current portion" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r70" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r57", "r200", "r215" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "ngen_CurrentNetInvestmentInLease": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "CurrentNetInvestmentInLease", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "The amount of current net investment in lease.", "label": "Current Net Investment In Lease", "terseLabel": "Current portion of net investment in lease (Note 12)", "verboseLabel": "Current portion" } } }, "auth_ref": [] }, "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current receivables from taxes other than income tax", "terseLabel": "Value added and other taxes receivable" } }, "en": { "role": { "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]" } } }, "auth_ref": [ "r261" ] }, "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails": { "parentTag": "ifrs-full_NetDeferredTaxAssets", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Deductible temporary differences for which no deferred tax asset is recognised", "negatedLabel": "Unrecognized deferred tax asset" } }, "en": { "role": { "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r5", "r136" ] }, "ngen_DeductibleTemporaryDifferencesUnusedTaxCreditsUnusedTaxLossesForWhichNoDeferredTaxAssetIsRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DeductibleTemporaryDifferencesUnusedTaxCreditsUnusedTaxLossesForWhichNoDeferredTaxAssetIsRecognized", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of deductible temporary differences, unused tax credits, unused tax losses for which no deferred tax asset is recognized in the statement of financial position.", "label": "Deductible Temporary Differences, Unused Tax Credits, Unused Tax Losses For Which No Deferred Tax Asset Is Recognized", "terseLabel": "Temporary differences, unused tax credits and unused tax losses not included in statements of financial position" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails": { "parentTag": "ifrs-full_NetDeferredTaxAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets", "terseLabel": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r6", "r137", "r196", "r198" ] }, "ifrs-full_DeferredTaxLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxLiabilityAsset", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax liability (asset)", "negatedLabel": "Deferred tax liability (asset)" } }, "en": { "role": { "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r6", "r137" ] }, "ngen_DepreciationExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DepreciationExpenseMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesGeneralAndAdministrationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to depreciation expense.", "label": "Depreciation Expense [Member]", "terseLabel": "Depreciation expense" } } }, "auth_ref": [] }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipment", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, property, plant and equipment", "negatedLabel": "Depreciation" } } }, "auth_ref": [ "r11", "r14", "r141" ] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationRightofuseAssets", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, right-of-use assets", "negatedLabel": "Amortization" } } }, "auth_ref": [ "r71", "r117" ] }, "ifrs-full_DerivativesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativesMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Derivatives [member]", "terseLabel": "Non-cash warrant derivative", "verboseLabel": "Warrant derivative" } }, "en": { "role": { "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r216", "r219", "r224", "r225" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for earnings per share [text block]", "terseLabel": "Basic and diluted loss per Common Share" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for earnings per share." } } }, "auth_ref": [ "r258" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for financial instruments [text block]", "terseLabel": "Financial instruments" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r258" ] }, "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForGovernmentGrants", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for government grants [text block]", "terseLabel": "Government assistance" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r17", "r144" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for income tax [text block]", "terseLabel": "Income taxes" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r258" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for intangible assets other than goodwill [text block]", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r258" ] }, "ngen_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's material accounting policy information for new accounting standards and interpretations.", "label": "Description Of Accounting Policy For New Accounting Standards And Interpretations [Policy Text Block]", "terseLabel": "New accounting standards and interpretations" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for property, plant and equipment [text block]", "terseLabel": "Property and equipment" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r258" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for provisions [text block]", "terseLabel": "Provisions" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r258" ] }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for research and development expense [text block]", "terseLabel": "Research and development costs" } } }, "auth_ref": [ "r258" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for share-based payment transactions [text block]", "terseLabel": "Stock-based compensation and retention securities" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r258" ] }, "ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForWarrantsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for warrants [text block]", "terseLabel": "Warrants issued in equity financing transactions" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for warrants. Warrants are financial instruments that give the holder the right to purchase ordinary shares." } } }, "auth_ref": [ "r258" ] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r44", "r126" ] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsFairValueOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected stock price volatility" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r95" ] }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfOptionLifeShareOptionsGranted", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsFairValueOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Option life, share options granted", "terseLabel": "Expected term in years" } }, "en": { "role": { "documentation": "The option life of share options granted." } } }, "auth_ref": [ "r95" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsFairValueOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk-free interest rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r95" ] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted net loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r26", "r27" ] }, "ngen_DirectorsAndEntitiesAssociatedWithPfpBioscienceHoldingsMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DirectorsAndEntitiesAssociatedWithPfpBioscienceHoldingsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for directors and entities associated with PFP Bioscience Holdings.", "label": "Directors And Entities Associated With PFP Bioscience Holdings [Member]", "terseLabel": "Directors and entities PFP bioscience holdings" } } }, "auth_ref": [] }, "ngen_DirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DirectorsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for directors.", "label": "Directors [Member]", "terseLabel": "Directors" } } }, "auth_ref": [] }, "ngen_DisclosureOfAccountingJudgementsAndEstimatesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DisclosureOfAccountingJudgementsAndEstimatesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Use of judgements and estimates" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureUseOfJudgementsAndEstimates" ], "lang": { "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Use of judgements and estimates" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r254" ] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesGeneralAndAdministrationExpenseDetails", "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesResearchAndDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [line items]", "terseLabel": "Nature of expenses" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesGeneralAndAdministrationExpenseDetails", "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesResearchAndDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [table]" } } }, "auth_ref": [ "r255", "r257" ] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureBasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]", "terseLabel": "Basis of presentation" } } }, "auth_ref": [ "r254" ] }, "ngen_DisclosureOfBasisOfPresentationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DisclosureOfBasisOfPresentationAbstract", "lang": { "en-us": { "role": { "documentation": "n/a.", "label": "Basis of presentation" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Share capital" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "terseLabel": "Schedule of number of shares outstanding and weighted average number of shares" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r122", "r177", "r204" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r122", "r177", "r204" ] }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCommitments" ], "lang": { "en-us": { "role": { "label": "Disclosure of commitments [text block]", "terseLabel": "Commitments" } }, "en": { "role": { "documentation": "The disclosure of commitments." } } }, "auth_ref": [ "r254" ] }, "ifrs-full_DisclosureOfDeferredTaxesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDeferredTaxesExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of deferred taxes [text block]", "terseLabel": "Schedule of deferred income tax" } }, "en": { "role": { "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r254" ] }, "ngen_DisclosureOfDerivativeFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DisclosureOfDerivativeFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "documentation": "n/a.", "label": "Warrant derivative" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDerivativeFinancialInstrumentsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivative" ], "lang": { "en-us": { "role": { "label": "Disclosure of derivative financial instruments [text block]", "terseLabel": "Warrant derivative" } }, "en": { "role": { "documentation": "The disclosure of derivative financial instruments. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r254" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIntangibleAssetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block]", "terseLabel": "Schedule of changes in intangible assets" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r34", "r155" ] }, "ngen_DisclosureOfDetailedInformationAboutLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DisclosureOfDetailedInformationAboutLeasesTableTextBlock", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure for leases.", "label": "Disclosure Of Detailed Information About Leases [Table Text Block]", "terseLabel": "Schedule of changes in the carrying amounts of the net investment in lease and lease liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [text block]", "terseLabel": "Schedule of changes in the carrying amounts of equipment" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r13", "r143" ] }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureSegmentReporting" ], "lang": { "en-us": { "role": { "label": "Disclosure of entity's operating segments [text block]", "terseLabel": "Segment reporting" } }, "en": { "role": { "documentation": "The entire disclosure for operating segments." } } }, "auth_ref": [ "r114" ] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "Subsequent events" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r1" ] }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfExpensesByNatureExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpenses" ], "lang": { "en-us": { "role": { "label": "Disclosure of expenses by nature [text block]", "terseLabel": "Nature of expenses" } } }, "auth_ref": [ "r254" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of liabilities [text block]", "terseLabel": "Schedule of reconciliation of change in fair value of warrant derivatives" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of liabilities." } } }, "auth_ref": [ "r67", "r175" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of liabilities [line items]", "terseLabel": "Financial risk management" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the fair value measurement of liabilities." } } }, "auth_ref": [ "r67", "r175" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial liabilities [line items]", "terseLabel": "Warrant derivative" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial liabilities." } } }, "auth_ref": [ "r105", "r169" ] }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialRiskManagementExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagement" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial risk management [text block]", "terseLabel": "Financial risk management" } }, "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } } }, "auth_ref": [ "r254" ] }, "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpenseTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of general and administrative expense [text block]", "terseLabel": "Schedule of general and administrative expense" } } }, "auth_ref": [ "r254" ] }, "ifrs-full_DisclosureOfGeographicalAreasLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureSegmentReportingDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of geographical areas [line items]", "terseLabel": "Segment reporting" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeographicalAreasTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureSegmentReportingDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of geographical areas [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to geographical areas." } } }, "auth_ref": [ "r113" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "Income taxes" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r8" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]", "terseLabel": "Schedule of assumptions for fair value of options granted" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } } }, "auth_ref": [ "r96" ] }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of information about key management personnel [text block]", "terseLabel": "Schedule of key management personnel" } }, "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r254" ] }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Intangible asset" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIntangibleAsset" ], "lang": { "en-us": { "role": { "label": "Disclosure of intangible assets [text block]", "terseLabel": "Intangible asset" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r36" ] }, "ngen_DisclosureOfLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DisclosureOfLeasesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Net investment in lease and lease liability" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfLeasesExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiability" ], "lang": { "en-us": { "role": { "label": "Disclosure of leases [text block]", "terseLabel": "Net investment in lease and lease liability" } }, "en": { "role": { "documentation": "The entire disclosure for leases." } } }, "auth_ref": [ "r75", "r76" ] }, "ifrs-full_DisclosureOfMarketRiskExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMarketRiskExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of market risk [text block]", "terseLabel": "Schedule of currency risk with balances in U.S. dollars and balances in Australian dollars" } }, "en": { "role": { "documentation": "The disclosure of market risk. [Refer: Market risk [member]]" } } }, "auth_ref": [ "r254" ] }, "ngen_DisclosureOfMaterialAccountingPolicyInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DisclosureOfMaterialAccountingPolicyInformationAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Material accounting policies" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of material accounting policy information [text block]", "terseLabel": "Material accounting policies" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r127", "r179", "r187" ] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Financial risk management" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementCurrencyRiskDetails", "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]", "terseLabel": "Financial risk management" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementCurrencyRiskDetails", "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments." } } }, "auth_ref": [ "r101", "r102" ] }, "ngen_DisclosureOfNatureOfBusinessAbstract": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DisclosureOfNatureOfBusinessAbstract", "lang": { "en-us": { "role": { "documentation": "n/a.", "label": "Nature of business" } } }, "auth_ref": [] }, "ngen_DisclosureOfNatureOfOperationsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DisclosureOfNatureOfOperationsTextBlock", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfBusiness" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for nature of business.", "label": "Disclosure Of Nature Of Operations [Text Block]", "terseLabel": "Nature of business" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Subsequent events" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]", "terseLabel": "Subsequent events" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } } }, "auth_ref": [ "r0", "r132" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]", "terseLabel": "Schedule of warrants transactions" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r252" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of share options [text block]", "terseLabel": "Schedule of stock option transactions" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r91", "r166" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]", "terseLabel": "Schedule of stock options outstanding" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r93" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]", "terseLabel": "Stock options, retention securities and warrants" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options." } } }, "auth_ref": [ "r93" ] }, "ngen_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingWarrantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingWarrantsTableTextBlock", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted average remaining contractual life of outstanding warrants.", "label": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Warrants [Table Text Block]", "terseLabel": "Schedule of warrants outstanding" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract", "lang": { "en-us": { "role": { "label": "Capital disclosures" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosures" ], "lang": { "en-us": { "role": { "label": "Disclosure of objectives, policies and processes for managing capital [text block]", "terseLabel": "Capital disclosures" } }, "en": { "role": { "documentation": "The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital." } } }, "auth_ref": [ "r188" ] }, "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of objectives, policies and processes for managing capital [line items]", "terseLabel": "Capital disclosures" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of objectives, policies and processes for managing capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the objectives, policies and processes for managing capital." } } }, "auth_ref": [ "r189" ] }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsAbstract", "lang": { "en-us": { "role": { "label": "Segment reporting" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssets" ], "lang": { "en-us": { "role": { "label": "Disclosure of prepayments and other assets [text block]", "terseLabel": "Prepaids, deposits, and other current assets" } }, "en": { "role": { "documentation": "The disclosure of prepayments and other assets. [Refer: Other assets; Prepayments]" } } }, "auth_ref": [ "r254" ] }, "ngen_DisclosureOfPrepaymentsDepositsAndOtherCurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DisclosureOfPrepaymentsDepositsAndOtherCurrentAssetsAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Prepaids, deposits, and other current assets" } } }, "auth_ref": [] }, "ngen_DisclosureOfPrepaymentsDepositsAndOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DisclosureOfPrepaymentsDepositsAndOtherCurrentAssetsTableTextBlock", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of prepayments, deposits and other current assets.", "label": "Disclosure Of Prepayments, Deposits And Other Current Assets [Table Text Block]", "terseLabel": "Schedule of prepaids, deposits, and other current assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and equipment" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Disclosure of property, plant and equipment [text block]", "terseLabel": "Property and equipment" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r15" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]", "terseLabel": "Property and equipment" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r13", "r143" ] }, "ngen_DisclosureOfReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DisclosureOfReceivablesTableTextBlock", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureReceivablesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of receivables.", "label": "Disclosure Of Receivables [Table Text Block]", "terseLabel": "Schedule of receivables" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnel" ], "lang": { "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "Key management personnel" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r24" ] }, "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpenseTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of research and development expense [text block]", "terseLabel": "Schedule of research and development expense" } } }, "auth_ref": [ "r254" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapital" ], "lang": { "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r123", "r178", "r205" ] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrants" ], "lang": { "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block]", "terseLabel": "Stock options, retention securities and warrants" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r84" ] }, "ngen_DisclosureOfSignificantObservableInputsUsedInFairValueMeasurementOfLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DisclosureOfSignificantObservableInputsUsedInFairValueMeasurementOfLiabilitiesTableTextBlock", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of significant observable inputs used in measuring the fair value of liabilities.", "label": "Disclosure Of Significant Observable Inputs Used In Fair Value Measurement Of Liabilities [Table Text Block]", "terseLabel": "Schedule of assumptions used in measuring estimated fair value of the warrant derivatives" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTaxReceivablesAndPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTaxReceivablesAndPayablesExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of tax receivables and payables [text block]", "terseLabel": "Schedule of components of the Company's temporary differences, unused tax credits and unused tax losses" } }, "en": { "role": { "documentation": "The disclosure of tax receivables and payables." } } }, "auth_ref": [ "r254" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails", "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "terseLabel": "Income taxes" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails", "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r7", "r138" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "lang": { "en-us": { "role": { "label": "Stock options, retention securities and warrants" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsFairValueOfOptionsGrantedDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsNarrativesDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "terseLabel": "Stock options, retention securities and warrants" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsFairValueOfOptionsGrantedDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsNarrativesDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r94", "r167" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilities" ], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Accounts payable and accrued liabilities" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r254" ] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureReceivables" ], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other receivables [text block]", "terseLabel": "Receivables" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r254" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "lang": { "en-us": { "role": { "label": "Key management personnel" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureBasisOfPresentationDetails", "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]", "terseLabel": "Key management personnel", "verboseLabel": "Basis of presentation" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureBasisOfPresentationDetails", "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r23", "r148" ] }, "ngen_DisclosureOfUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "DisclosureOfUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of useful life of property plant and equipment.", "label": "Disclosure Of Useful Life Of Property, Plant And Equipment [Table Text Block]", "terseLabel": "Summary of expected life of the assets" } } }, "auth_ref": [] }, "ifrs-full_DisposalsAndRetirementsRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsAndRetirementsRightofuseAssets", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails", "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Disposals and retirements, right-of-use assets", "negatedLabel": "Derecognition", "verboseLabel": "Derecognition of right-of-use-asset" } }, "en": { "role": { "documentation": "The decrease in right-of-use assets resulting from disposals and retirements. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r245" ] }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disposals, property, plant and equipment", "negatedLabel": "Disposals" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r10", "r140" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r236", "r237", "r238" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r236", "r237", "r238", "r239" ] }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)." } } }, "auth_ref": [ "r236", "r237", "r238", "r239" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "terseLabel": "Document Information", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r232" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Effect of foreign exchange on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r40", "r41" ] }, "ngen_EntitiesAssociatedWithPfpBioscienceHoldingsMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "EntitiesAssociatedWithPfpBioscienceHoldingsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for entities associated with PFP Bioscience Holdings.", "label": "Entities Associated With PFP Bioscience Holdings [Member]", "terseLabel": "Entities with PFP Bioscience Holdings" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r234" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r234" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r241" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r240" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPrimarySicNumber", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r238" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r234" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r234" ] }, "ngen_EquipmentAndLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "EquipmentAndLicenseMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails", "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits attributable to equipment and licenses.", "label": "Equipment and License [Member]", "terseLabel": "Equipment and license" } } }, "auth_ref": [] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance ending", "periodStartLabel": "Balance balance", "totalLabel": "Shareholders' Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r50", "r52", "r62", "r63", "r66", "r149", "r158", "r172", "r173", "r181", "r197", "r202" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Shareholders' Equity", "verboseLabel": "Total Shareholders' Equity" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Liabilities and Shareholders' Equity" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r197" ] }, "ngen_ExercisePrice1.00To1.50Member": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ExercisePrice1.00To1.50Member", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for exercise price range of $1.01-$1.50.", "label": "Exercise Price 1.00 to 1.50 [Member]", "terseLabel": "1.01-1.50" } } }, "auth_ref": [] }, "ngen_ExercisePrice1.51To2.00Member": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ExercisePrice1.51To2.00Member", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for exercise price range of $1.51-$2.00.", "label": "Exercise Price 1.51 to 2.00 [Member]", "terseLabel": "1.51-2.00" } } }, "auth_ref": [] }, "ngen_ExercisePrice2.00To2.50Member": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ExercisePrice2.00To2.50Member", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for exercise price range of $2.01-$2.50.", "label": "Exercise Price 2.00 to 2.50 [Member]", "terseLabel": "2.01-2.50" } } }, "auth_ref": [] }, "ngen_ExercisePrice2.51To3.00Member": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ExercisePrice2.51To3.00Member", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for exercise price range of $2.51-$3.00.", "label": "Exercise Price 2.51 to 3.00 [Member]", "terseLabel": "2.51-3.00" } } }, "auth_ref": [] }, "ngen_ExercisePrice3.00To3.50Member": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ExercisePrice3.00To3.50Member", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for exercise price range of $3.01-$3.50.", "label": "Exercise Price 3.00 to 3.50 [Member]", "terseLabel": "3.01-3.50" } } }, "auth_ref": [] }, "ngen_ExercisePrice3.51To4.00Member": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ExercisePrice3.51To4.00Member", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for exercise price range of $3.51-$4.00.", "label": "Exercise Price 3.51 to 4.00 [Member]", "terseLabel": "3.51-4.00" } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExercisePriceOfOutstandingShareOptions2019", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price of outstanding share options", "terseLabel": "Exercise Price ($)" } }, "en": { "role": { "documentation": "The exercise price of outstanding share options." } } }, "auth_ref": [ "r93" ] }, "ngen_ExercisePriceOfWarrantsExercised": { "xbrltype": "perShareItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ExercisePriceOfWarrantsExercised", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants exercised during period.", "label": "Exercise Price of Warrants, Exercised", "terseLabel": "Weighted average exercise price, Exercised" } } }, "auth_ref": [] }, "ngen_ExercisePriceOfWarrantsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ExercisePriceOfWarrantsGranted", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants granted during period.", "label": "Exercise Price of Warrants, Granted", "terseLabel": "Weighted average exercise price, Granted" } } }, "auth_ref": [] }, "ngen_ExercisePriceOfWarrantsOutstanding": { "xbrltype": "perShareItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ExercisePriceOfWarrantsOutstanding", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants outstanding.", "label": "Exercise Price of Warrants, Outstanding", "periodEndLabel": "Weighted average exercise price, Ending balance", "periodStartLabel": "Weighted average exercise price, Beginning balance" } } }, "auth_ref": [] }, "ifrs-full_ExpenseByNatureAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseByNatureAbstract", "lang": { "en-us": { "role": { "label": "Nature of expenses" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions", "terseLabel": "Stock-based compensation expense" } } }, "auth_ref": [ "r98", "r168" ] }, "ngen_FairValueOfBrokerWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "FairValueOfBrokerWarrants", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Fair value of broker warrants.", "label": "Fair Value Of Broker Warrants", "terseLabel": "Finder's/Broker's warrants", "verboseLabel": "Fair value of broker warrants" } } }, "auth_ref": [] }, "ngen_FairValueOfOptionsAllocatedToShareCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "FairValueOfOptionsAllocatedToShareCapital", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Fair value of options allocated to share capital.", "label": "Fair Value Of Options Allocated To Share Capital", "terseLabel": "Fair value of options allocated to share capital" } } }, "auth_ref": [] }, "ngen_FairValueOfWarrantsAllocatedToShareCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "FairValueOfWarrantsAllocatedToShareCapital", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Fair value of warrants allocated to share capital.", "label": "Fair Value of Warrants Allocated To Share capital", "terseLabel": "Fair value of warrants allocated to share capital" } } }, "auth_ref": [] }, "ngen_FederalScientificResearchExperimentalDevelopmentInvestmentTaxCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "FederalScientificResearchExperimentalDevelopmentInvestmentTaxCreditMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits attributable to Federal Scientific Research & Experimental Development Investment Tax Credit..", "label": "Federal Scientific Research & Experimental Development Investment Tax Credit [Member]", "terseLabel": "Federal SRED ITC" } } }, "auth_ref": [] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Finance income", "negatedLabel": "Interest income" } } }, "auth_ref": [ "r264" ] }, "ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets measured at fair value through other comprehensive income", "terseLabel": "Financial assets measured under fair value through other comprehensive income" } }, "en": { "role": { "documentation": "The amount of financial assets that are measured at fair value through other comprehensive income. A financial asset shall be measured at fair value through other comprehensive income if both of the following conditions are met: (a) the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r106", "r170" ] }, "ifrs-full_FinancialEffectOfCorrectionsOfAccountingErrorsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialEffectOfCorrectionsOfAccountingErrorsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfCashFlowsDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) due to corrections of prior period errors [member]", "terseLabel": "Restatement Adjustments" } }, "en": { "role": { "documentation": "This member stands for the financial effect of corrections of prior period errors." } } }, "auth_ref": [ "r48", "r49", "r130", "r131" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, at fair value", "terseLabel": "Fair value of financial liabilities" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r100" ] }, "ifrs-full_FixturesAndFittingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FixturesAndFittingsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Fixtures and fittings [member]", "terseLabel": "Fixtures and fittings" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r210" ] }, "ngen_FormerChairmanOfBoardOfDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "FormerChairmanOfBoardOfDirectorsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for former Chairman of Board of Directors.", "label": "Former Chairman Of Board Of Directors [Member]", "terseLabel": "Former Chairman Of Board Of Directors" } } }, "auth_ref": [] }, "ngen_FormerChiefMedicalOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "FormerChiefMedicalOfficerMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for former Chief Medical Officer.", "label": "Former Chief Medical Officer [Member]", "terseLabel": "Former Chief Medical Officer" } } }, "auth_ref": [] }, "ngen_FormerPresidentAndChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "FormerPresidentAndChiefExecutiveOfficerMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the former President and Chief Executive Officer.", "label": "Former President and Chief Executive Officer [Member]", "terseLabel": "Former President and Chief Executive Officer" } } }, "auth_ref": [] }, "ngen_FrsPriorPeriodAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "FrsPriorPeriodAdjustmentAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Restatement of Prior Period Financial Statements" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Foreign exchange gain (loss)", "negatedLabel": "Foreign exchange loss (gain)" } }, "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r18", "r145", "r190" ] }, "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities", "terseLabel": "Change in fair value of warrant derivative" } }, "en": { "role": { "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r64", "r174" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesGeneralAndAdministrationExpenseDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative expense", "terseLabel": "General and administration expenses", "verboseLabel": "General and administrative (Note 20)" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/DisclosureSegmentReportingDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r113", "r211", "r221", "r223", "r226" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/DisclosureSegmentReportingDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r113", "r211", "r221", "r223", "r226" ] }, "ngen_GrantsNumberOfMilestonesAchieved": { "xbrltype": "integerItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "GrantsNumberOfMilestonesAchieved", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCommitmentDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of milestones achieved in the grants.", "label": "Grants, Number of Milestones Achieved", "terseLabel": "Number of milestones achieved" } } }, "auth_ref": [] }, "ngen_GrantsTotalNumberOfMilestones": { "xbrltype": "integerItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "GrantsTotalNumberOfMilestones", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCommitmentDetails" ], "lang": { "en-us": { "role": { "documentation": "The total number of milestones in the grants.", "label": "Grants, Total Number of Milestones", "terseLabel": "Total number of milestones" } } }, "auth_ref": [] }, "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "HistoricalVolatilityForSharesMeasurementInputMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Historical volatility for shares, measurement input [member]", "terseLabel": "Expected stock price volatility" } }, "en": { "role": { "documentation": "This member stands for the historical volatility for shares used as a measurement input." } } }, "auth_ref": [ "r217" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r236", "r237", "r238" ] }, "ngen_IfrsClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsClassOfWarrantOrRightAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "IFRS Class of Warrant or Right [Axis]", "terseLabel": "IFRS Class of Warrant or Right [Axis]" } } }, "auth_ref": [] }, "ngen_IfrsClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsClassOfWarrantOrRightDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding.", "label": "IFRS Class of Warrant or Right [Domain]", "terseLabel": "IFRS Class of Warrant or Right [Domain]" } } }, "auth_ref": [] }, "ngen_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Ifrs Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrant" } } }, "auth_ref": [] }, "ngen_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Ifrs Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of shares for each warrant" } } }, "auth_ref": [] }, "ngen_IfrsClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsClassOfWarrantOrRightOutstanding", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Ifrs Class of Warrant or Right, Outstanding", "periodEndLabel": "Number of shares issuable under warrants, Ending balance", "periodStartLabel": "Number of shares issuable under warrants, Beginning balance", "terseLabel": "Warrants outstanding" } } }, "auth_ref": [] }, "ngen_IfrsDeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsDeferredOfferingCosts", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Ifrs Deferred Offering Costs", "terseLabel": "Deferred Share Issuance Costs (Note 17)" } } }, "auth_ref": [] }, "ngen_IfrsErrorCorrectionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsErrorCorrectionTextBlock", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatements" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting error correction.", "label": "IFRS Error Correction [Text Block]", "terseLabel": "Restatement of Prior Period Financial Statements" } } }, "auth_ref": [] }, "ngen_IfrsErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfCashFlowsDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "IFRS Error Corrections and Prior Period Adjustments Restatement [Line Items]", "terseLabel": "Restatement of Prior Period Financial Statements" } } }, "auth_ref": [] }, "ngen_IfrsGrantsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsGrantsReceivableCurrent", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "IFRS Grants Receivable, Current", "terseLabel": "Grants receivable" } } }, "auth_ref": [] }, "ngen_IfrsMajorityShareholderMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsMajorityShareholderMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for majority shareholder.", "label": "IFRS Majority Shareholder [Member]", "terseLabel": "Majority Shareholder" } } }, "auth_ref": [] }, "ngen_IfrsMeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsMeasurementInputExpectedTermMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Ifrs Measurement Input, Expected Term [Member]", "terseLabel": "Expected warrant life in years" } } }, "auth_ref": [] }, "ngen_IfrsMeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsMeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Ifrs Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free interest rate" } } }, "auth_ref": [] }, "ngen_IfrsMeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsMeasurementInputTypeAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Ifrs Measurement Input Type [Axis]" } } }, "auth_ref": [] }, "ngen_IfrsMeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsMeasurementInputTypeDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Ifrs Measurement Input Type [Domain]" } } }, "auth_ref": [] }, "ngen_IfrsNoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsNoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Ifrs Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash transactions:" } } }, "auth_ref": [] }, "ngen_IfrsNumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsNumberOfOperatingSegments", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureSegmentReportingDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "IFRS Number Of Operating Segments", "terseLabel": "Number of operating segment" } } }, "auth_ref": [] }, "ngen_IfrsNumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsNumberOfReportableSegments", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureSegmentReportingDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "IFRS Number Of Reportable Segments", "terseLabel": "Number of reportable segment" } } }, "auth_ref": [] }, "ngen_IfrsPrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsPrepaidInsurance", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails": { "parentTag": "ngen_PrepaymentsDepositsAndOtherCurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "IFRS Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "auth_ref": [] }, "ngen_IfrsSaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsSaleOfStockAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosuresDetails", "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "IFRS Sale of Stock [Axis]", "terseLabel": "IFRS Sale of Stock [Axis]" } } }, "auth_ref": [] }, "ngen_IfrsSaleOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsSaleOfStockDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosuresDetails", "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "IFRS Sale of Stock [Domain]", "terseLabel": "IFRS Sale of Stock [Domain]" } } }, "auth_ref": [] }, "ngen_IfrsSaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsSaleOfStockPricePerShare", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Ifrs Sale of Stock, Price Per Share", "terseLabel": "Purchase price" } } }, "auth_ref": [] }, "ngen_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "IFRS Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of income taxes at statutory rates with the reported taxes" } } }, "auth_ref": [] }, "ngen_IfrsScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.", "label": "IFRS Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "terseLabel": "Summary of impact of the correction of the misstatements" } } }, "auth_ref": [] }, "ngen_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition.", "label": "IFRS Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "auth_ref": [] }, "ngen_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options.", "label": "IFRS Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted average remaining contractual life" } } }, "auth_ref": [] }, "ngen_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "xbrltype": "durationItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of award under share-based payment arrangement.", "label": "IFRS Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award", "terseLabel": "Term of award" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Loss and Comprehensive Loss" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Tax expense (income)", "totalLabel": "Total income tax expense (recovery)" } } }, "auth_ref": [ "r2", "r3", "r4", "r25", "r61", "r108", "r133", "r134", "r135", "r208" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r43", "r125" ] }, "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNumberOfSharesOutstanding", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalScheduleOfNumberOfSharesOutstandingAndWeightedAverageNumberOfSharesDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in number of shares outstanding", "terseLabel": "Shares issued" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]" } } }, "auth_ref": [ "r121", "r176", "r203" ] }, "ngen_IncreaseDecreaseInProfitLossDueToReasonablyPossibleChangeInRiskVariable": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IncreaseDecreaseInProfitLossDueToReasonablyPossibleChangeInRiskVariable", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in profit (loss) that would have been caused by a reasonably possible decrease (increase) in the risk variable", "label": "Increase (Decrease) In Profit (Loss) Due To Reasonably Possible Change In Risk Variable", "terseLabel": "Increase or decrease in loss and comprehensive loss due to change in risk variable" } } }, "auth_ref": [] }, "ngen_IncreaseDecreaseThroughBrokerWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IncreaseDecreaseThroughBrokerWarrantsEquity", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from the broker warrants.", "label": "Increase (Decrease) Through Broker Warrants, Equity", "terseLabel": "Broker warrants (Note 17)" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfOptions", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through exercise of options, equity", "terseLabel": "Option exercises (Note 18)" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } } }, "auth_ref": [ "r256" ] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through exercise of warrants, equity", "terseLabel": "Warrant exercise (Note 18)" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } } }, "auth_ref": [ "r256" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Stock-based compensation (Note 18)" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r185" ] }, "ngen_IncreaseDecreaseThroughWarrantAmendmentEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IncreaseDecreaseThroughWarrantAmendmentEquity", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from the warrant amendments.", "label": "Increase (Decrease) Through Warrant Amendment, Equity", "terseLabel": "Warrant amendment (Note 16)" } } }, "auth_ref": [] }, "ngen_IncreaseInNumberOfSharesOutstandingOptionExercises": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IncreaseInNumberOfSharesOutstandingOptionExercises", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase in number of shares outstanding through option exercises.", "label": "Increase In Number Of Shares Outstanding, Option Exercises", "terseLabel": "Option exercises (Note 18) (in shares)", "verboseLabel": "Number of shares issued for option exercises" } } }, "auth_ref": [] }, "ngen_IncreaseInNumberOfSharesOutstandingSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IncreaseInNumberOfSharesOutstandingSharesIssued", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosuresDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase in number of shares outstanding through new issues.", "label": "Increase In Number Of Shares Outstanding, Shares Issued", "terseLabel": "Common share financings, net (Note 17 (in shares)", "verboseLabel": "Number of shares issued and sold" } } }, "auth_ref": [] }, "ngen_IncreaseInNumberOfSharesOutstandingWarrantExercises": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "IncreaseInNumberOfSharesOutstandingWarrantExercises", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase in number of shares outstanding through warrant exercises..", "label": "Increase In Number Of Shares Outstanding, Warrant Exercises", "terseLabel": "Warrant exercise (Note 18) (in shares)", "verboseLabel": "Number of shares issued for warrant exercises" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIntangibleAssetDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill", "periodEndLabel": "Balance ending", "periodStartLabel": "Balance beginning", "terseLabel": "Intangible assets, net (Note 13)" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r33", "r154", "r192" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense on lease liabilities", "terseLabel": "Lease interest" } } }, "auth_ref": [ "r72", "r118" ] }, "ngen_InvestorAndPublicRelationsExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "InvestorAndPublicRelationsExpenseMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesGeneralAndAdministrationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to investor and public relations expenses.", "label": "Investor and Public Relations Expense [Member]", "terseLabel": "Investor and public relations" } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Common share financings, net (Note 17)", "verboseLabel": "Value of equity issued" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r185" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Issued capital", "terseLabel": "Common shares (Note 17)" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r228", "r230" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issued capital [member]", "terseLabel": "Common Shares" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r186" ] }, "ifrs-full_IssuesFairValueMeasurementLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuesFairValueMeasurementLiabilities", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Issues, fair value measurement, liabilities", "terseLabel": "Recognition of warrant derivative" } }, "en": { "role": { "documentation": "The increase in fair value measurement of liabilities resulting from issues of those liabilities. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r65" ] }, "ngen_July2022PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "July2022PrivatePlacementMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for July 2022 private placement", "label": "July 2022 Private Placement [Member]", "terseLabel": "July 2022 private placement" } } }, "auth_ref": [] }, "ngen_July2022WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "July2022WarrantsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for July 22 Warrants.", "label": "July 2022, Warrants [Member]", "terseLabel": "July '22 Warrants" } } }, "auth_ref": [] }, "ngen_KeyManagementPersonnelAccruedBonusPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "KeyManagementPersonnelAccruedBonusPayment", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow as bonus payment to key management personnel for the services rendered.", "label": "Key Management Personnel, Accrued Bonus Payment", "terseLabel": "Accrued bonus" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation", "terseLabel": "Salary compensation", "totalLabel": "Total" } } }, "auth_ref": [ "r22", "r147" ] }, "ngen_KeyManagementPersonnelCompensationConsultingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "KeyManagementPersonnelCompensationConsultingFees", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of compensation to key management personnel in the form of consulting fees for the services rendered by them to the entity.", "label": "Key management personnel compensation, Consulting Fees", "terseLabel": "Consulting" } } }, "auth_ref": [] }, "ngen_KeyManagementPersonnelCompensationConsultingFeesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "KeyManagementPersonnelCompensationConsultingFeesPaid", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of compensation to key management personnel in the form of consulting fees paid for the services rendered by them to the entity.", "label": "Key management Personnel Compensation, Consulting Fees Paid", "terseLabel": "Consulting service fees" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "terseLabel": "Stock-based compensation" } } }, "auth_ref": [ "r21" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation, short-term employee benefits", "terseLabel": "Salaries and bonuses" } } }, "auth_ref": [ "r20" ] }, "ngen_KeyManagementPersonnelPaymentsForAccruedVacationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "KeyManagementPersonnelPaymentsForAccruedVacationCosts", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow for payment of vacation costs that were accrued to key management personnel.", "label": "Key Management Personnel, Payments For Accrued Vacation Costs", "terseLabel": "Accrued vacation" } } }, "auth_ref": [] }, "ngen_KeyManagementPersonnelShortTermEmployeeBenefitsAccrualsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "KeyManagementPersonnelShortTermEmployeeBenefitsAccrualsCurrent", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of short-term employee benefits accrued and payable by the entity to key management personnel, classified as current.", "label": "Key Management Personnel, Short Term Employee Benefits Accruals, Current", "terseLabel": "Expense reimbursements, accrued bonuses, and accrued vacation" } } }, "auth_ref": [] }, "ngen_LeaseInterestNetInvestmentInFinanceLease": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "LeaseInterestNetInvestmentInFinanceLease", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase in the net investment in finance lease resulting from lease interest earned.", "label": "Lease Interest, Net Investment In Finance Lease", "terseLabel": "Lease interest" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities", "periodEndLabel": "Balance at ending", "periodStartLabel": "Balance at beginning" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r70" ] }, "ifrs-full_LeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilitiesAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities [abstract]", "terseLabel": "Lease Liability" } } }, "auth_ref": [] }, "ngen_LeasePaymentsNetInvestmentInFinanceLease": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "LeasePaymentsNetInvestmentInFinanceLease", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails" ], "lang": { "en-us": { "role": { "documentation": "The decrease in the net investment in finance lease resulting from lease proceeds received.", "label": "Lease Payments, Net Investment In Finance Lease", "negatedLabel": "Lease payments" } } }, "auth_ref": [] }, "ngen_LegalProfessionalAndFinanceExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "LegalProfessionalAndFinanceExpenseMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesGeneralAndAdministrationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to legal, professional and finance expenses.", "label": "Legal, Professional and Finance Expense [Member]", "terseLabel": "Legal, professional and finance" } } }, "auth_ref": [] }, "ifrs-full_Level2OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level2OfFairValueHierarchyMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Level 2 of fair value hierarchy [member]", "terseLabel": "Level 2" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } } }, "auth_ref": [ "r29", "r30", "r63", "r151", "r173" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r16", "r63", "r173" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [domain]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r16", "r63", "r173" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities", "periodEndLabel": "Liabilities", "periodStartLabel": "Liabilities", "totalLabel": "Liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r62", "r63", "r66", "r109", "r112", "r172", "r173", "r197" ] }, "ifrs-full_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities [abstract]", "terseLabel": "Liabilities" } } }, "auth_ref": [] }, "ngen_LicensingAgreementAnnualMinimumRoyaltyPaymentPerYear": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "LicensingAgreementAnnualMinimumRoyaltyPaymentPerYear", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIntangibleAssetDetails" ], "lang": { "en-us": { "role": { "documentation": "Annual minimum royalty payment the entity is required to pay under the license agreement.", "label": "Licensing Agreement, Annual Minimum Royalty Payment Per Year", "terseLabel": "Annual minimum royalty" } } }, "auth_ref": [] }, "ngen_LicensingAgreementMaximumRemainingMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "LicensingAgreementMaximumRemainingMilestonePayments", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIntangibleAssetDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum amount of remaining milestone payments as of the balance sheet date payable by the entity under the license agreement.", "label": "Licensing Agreement, Maximum Remaining Milestone Payments", "terseLabel": "Maximum remaining milestone payments" } } }, "auth_ref": [] }, "ngen_LicensingAgreementMilestonePaymentUponAchievementOfFutureClinicalDevelopmentMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "LicensingAgreementMilestonePaymentUponAchievementOfFutureClinicalDevelopmentMilestone", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIntangibleAssetDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of milestone payments the entity is obliged to pay upon achievement of future development milestones under the licensing agreement.", "label": "Licensing Agreement, Milestone Payment Upon Achievement Of Future Clinical Development Milestone", "terseLabel": "Project milestones payable" } } }, "auth_ref": [] }, "ngen_LicensingAgreementPaymentsForMilestonesAchieved": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "LicensingAgreementPaymentsForMilestonesAchieved", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIntangibleAssetDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for milestone that were achieved during the period.", "label": "Licensing Agreement, Payments For Milestones Achieved", "terseLabel": "Payments for milestone" } } }, "auth_ref": [] }, "ngen_LicensingAgreementRemainingMilestonePaymentsDueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "LicensingAgreementRemainingMilestonePaymentsDueCurrent", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIntangibleAssetDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of milestone payments due and payable within one year by the entity under the license agreement.", "label": "Licensing Agreement, Remaining Milestone Payments Due, Current", "terseLabel": "Milestone payments due in next 12 months" } } }, "auth_ref": [] }, "ngen_LicensingAndPatentLegalFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "LicensingAndPatentLegalFeesMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesResearchAndDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to licensing and patent legal fees.", "label": "Licensing and Patent Legal Fees [Member]", "terseLabel": "Licensing and patent legal fees" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ifrs-full_LossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LossesOnChangeInFairValueOfDerivatives", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Losses on change in fair value of derivatives", "terseLabel": "Unrealized loss on warrant derivative (Note 16)" } }, "en": { "role": { "documentation": "The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r264" ] }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "lang": { "en-us": { "role": { "label": "Income taxes" } } }, "auth_ref": [] }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MajorOrdinaryShareTransactionsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Major ordinary share transactions [member]", "terseLabel": "Major ordinary share transactions" } }, "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r209", "r227" ] }, "ngen_March2024BoughtDealFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "March2024BoughtDealFinancingMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for March 2024 bought deal financing.", "label": "March 2024 Bought Deal Financing [Member]", "terseLabel": "March 2024 bought deal financing" } } }, "auth_ref": [] }, "ngen_MaximumSharesSaleableAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "MaximumSharesSaleableAmount", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosuresDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum amount of shares issuable.", "label": "Maximum Shares Saleable, Amount", "terseLabel": "Maximum amount of shares to be sold" } } }, "auth_ref": [] }, "ngen_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement": { "xbrltype": "durationItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesStockBasedCompensationAndRetentionSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum term of options granted under a share-based payment arrangement during the period.", "label": "Maximum Term Of Options Granted For Share-Based Payment Arrangement", "terseLabel": "Expiration term of options" } } }, "auth_ref": [] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r37", "r38", "r62", "r157", "r172" ] }, "ifrs-full_MeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Measurement [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r37", "r38", "r62", "r157", "r172" ] }, "ifrs-full_NetDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetDeferredTaxAssets", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Net deferred tax assets", "totalLabel": "Net deferred tax assets" } }, "en": { "role": { "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r242" ] }, "ifrs-full_NetInvestmentInFinanceLease": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetInvestmentInFinanceLease", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails" ], "lang": { "en-us": { "role": { "label": "Net investment in finance lease", "periodEndLabel": "Balance at ending", "periodStartLabel": "Balance at beginning" } }, "en": { "role": { "documentation": "The gross investment in the finance lease discounted at the interest rate implicit in the lease. Finance lease is a lease that transfers substantially all the risks and rewards incidental to ownership of an underlying asset. Gross investment in the finance lease is the sum of: (a) the lease payments receivable by a lessor under a finance lease; and (b) any unguaranteed residual value accruing to the lessor. Interest rate implicit in the lease is the rate of interest that causes the present value of (a) the lease payments and (b) the unguaranteed residual value to equal to the sum of (i) the fair value of the underlying asset and (ii) the initial direct costs of the lessor." } } }, "auth_ref": [ "r74", "r120" ] }, "ngen_NetInvestmentInFinanceLeaseRealEstateFeesCommissionsAndAdministrativeCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NetInvestmentInFinanceLeaseRealEstateFeesCommissionsAndAdministrativeCharges", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of real estate fees, commissions and administrative charges pursuant to net investment in finance lease.", "label": "Net Investment In Finance Lease, Real Estate Fees, Commissions And Administrative Charges", "verboseLabel": "Real estate fees, commissions and administrative charges" } } }, "auth_ref": [] }, "ngen_NetInvestmentInFinanceLeaseRentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NetInvestmentInFinanceLeaseRentExpense", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of rent expense pursuant to net investment in finance lease.", "label": "Net Investment In Finance Lease, Rent Expense", "verboseLabel": "Rent expense" } } }, "auth_ref": [] }, "ngen_NetInvestmentInFinanceLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NetInvestmentInFinanceLeaseTermOfContract", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "The term of net investment in lease arrangement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Net Investment In Finance Lease, Term Of Contract", "verboseLabel": "Term of net investment in sublease" } } }, "auth_ref": [] }, "ngen_NetInvestmentsInFinanceLeaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NetInvestmentsInFinanceLeaseAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Net Investments In Finance Lease [Abstract]", "terseLabel": "Net Investment in Lease" } } }, "auth_ref": [] }, "ifrs-full_NetworkInfrastructureMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetworkInfrastructureMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Network infrastructure [member]", "terseLabel": "Network equipment and setup" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing network infrastructure. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r244" ] }, "ngen_NonCashWorkingCapitalChangesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NonCashWorkingCapitalChangesAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "n/a.", "label": "Non-cash Working Capital Changes [Abstract]", "terseLabel": "Changes in non-cash working capital:" } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureBasisOfPresentationDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r132" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureBasisOfPresentationDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r132" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r56", "r199", "r215" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current assets" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current lease liabilities", "terseLabel": "Lease liability (Note 12)", "verboseLabel": "Non-current portion" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r70" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r58", "r200", "r215" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Non-current liabilities" } } }, "auth_ref": [] }, "ngen_NoncurrentNetInvestmentInLease": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NoncurrentNetInvestmentInLease", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "The amount of noncurrent net investment in lease.", "label": "Noncurrent Net Investment In Lease", "terseLabel": "Net investment in lease (Note 12)", "verboseLabel": "Non-current portion" } } }, "auth_ref": [] }, "ngen_November2025PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "November2025PrivatePlacementMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for November 2025 private placement.", "label": "November 2025 Private Placement [Member]", "terseLabel": "November 2025 private placement" } } }, "auth_ref": [] }, "ngen_November2025WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "November2025WarrantsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for November 2025 Warrants.", "label": "November 2025, Warrants [Member]", "terseLabel": "November '25 Warrants" } } }, "auth_ref": [] }, "ngen_NumberOfCashGeneratingUnitsForImpairmentTesting": { "xbrltype": "integerItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NumberOfCashGeneratingUnitsForImpairmentTesting", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of cash generating units for the purpose of impairment testing.", "label": "Number of Cash Generating Units For Impairment Testing", "terseLabel": "Number of cash generating units for impairment testing" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Number of awards granted" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r97", "r252" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercisable in share-based payment arrangement", "terseLabel": "Number of awards exercisable" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r252" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments forfeited in share-based payment arrangement", "terseLabel": "Number of securities forfeited", "verboseLabel": "Equity instruments forfeited" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r252" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options outstanding in share-based payment arrangement", "periodEndLabel": "Number of shares issuable under options outstanding, ending balance", "periodStartLabel": "Number of shares issuable under options outstanding, beginning balance", "terseLabel": "Number of Options Outstanding", "verboseLabel": "Options outstanding" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r85", "r89", "r93", "r160", "r164" ] }, "ngen_NumberOfSecuritiesCalledByEachOtherEquityInstruments": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NumberOfSecuritiesCalledByEachOtherEquityInstruments", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued upon exercise of each other equity instruments under the share-based payment arrangement.", "label": "Number of Securities Called by Each Other Equity Instruments", "terseLabel": "Number of shares upon exercise of each security" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options exercisable in share-based payment arrangement", "terseLabel": "Number of Options Exercisable", "verboseLabel": "Options exercisable" } }, "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r90", "r165" ] }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsTransactionsDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options exercised in share-based payment arrangement", "negatedLabel": "Number of shares issuable under options outstanding, Exercised", "terseLabel": "Number of options exercised" } }, "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } } }, "auth_ref": [ "r88", "r163" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options forfeited in share-based payment arrangement", "terseLabel": "Options forfeited" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r87", "r162" ] }, "ngen_NumberOfShareOptionsForfeitedOrExpiredInShareBasedPaymentArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NumberOfShareOptionsForfeitedOrExpiredInShareBasedPaymentArrangement", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of share options forfeited or expired in a share-based payment arrangement.", "label": "Number Of Share Options Forfeited or Expired In Share-based Payment Arrangement", "negatedLabel": "Number of shares issuable under options outstanding, Forfeited/Expired" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options granted in share-based payment arrangement", "terseLabel": "Number of shares issuable under options outstanding, Granted" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r86", "r161" ] }, "ngen_NumberOfSharesForEachUnit": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NumberOfSharesForEachUnit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares for each unit.", "label": "Number Of Shares For Each Unit", "terseLabel": "Number of shares for each unit" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalScheduleOfNumberOfSharesOutstandingAndWeightedAverageNumberOfSharesDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares issued", "terseLabel": "Common Shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r256" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalScheduleOfNumberOfSharesOutstandingAndWeightedAverageNumberOfSharesDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding", "periodEndLabel": "Balance ending (in shares)", "periodStartLabel": "Beginning balance (in shares)" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r121", "r176", "r203" ] }, "ngen_NumberOfSharesOwned": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NumberOfSharesOwned", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of the company owned.", "label": "Number of Shares Owned", "terseLabel": "Number of shares owned" } } }, "auth_ref": [] }, "ngen_NumberOfWarrantsExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NumberOfWarrantsExercisedDuringPeriod", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants exercised during period.", "label": "Number Of Warrants Exercised During Period", "terseLabel": "Number of warrants exercised" } } }, "auth_ref": [] }, "ngen_NumberOfWarrantsForEachUnit": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NumberOfWarrantsForEachUnit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants for each unit.", "label": "Number Of Warrants For Each Unit", "terseLabel": "Number of warrants for each unit" } } }, "auth_ref": [] }, "ngen_NumberOfWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NumberOfWarrantsIssued", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued.", "label": "Number Of Warrants Issued", "terseLabel": "Number of warrants issued" } } }, "auth_ref": [] }, "ngen_NumberOfWhollyOwnedSubsidiaries": { "xbrltype": "integerItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "NumberOfWhollyOwnedSubsidiaries", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of wholly owned subsidiaries.", "label": "Number Of Wholly Owned Subsidiaries", "terseLabel": "Number of wholly owned subsidiaries" } } }, "auth_ref": [] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating expense", "totalLabel": "Total operating expenses" } } }, "auth_ref": [ "r264" ] }, "ngen_OperatingExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "OperatingExpenseAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "documentation": "n/a.", "label": "Operating Expense [Abstract]", "terseLabel": "Operating expenses" } } }, "auth_ref": [] }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherAdjustmentsForNoncashItems", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Other adjustments for non-cash items", "terseLabel": "Other items not involving cash and changes in non-cash working capital" } } }, "auth_ref": [ "r249" ] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureSegmentReportingDetails" ], "lang": { "en-us": { "role": { "label": "Other current assets", "terseLabel": "Other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r260" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other current payables", "terseLabel": "Other" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r260" ] }, "ngen_OtherGeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "OtherGeneralAndAdministrativeExpenseMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesGeneralAndAdministrationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to other general and administrative expenses.", "label": "Other General and Administrative Expense [Member]", "terseLabel": "Other general and administrative" } } }, "auth_ref": [] }, "ngen_OtherResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "OtherResearchAndDevelopmentExpenseMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesResearchAndDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to other research and development expense.", "label": "Other Research and Development Expense [Member]", "terseLabel": "Other research and development" } } }, "auth_ref": [] }, "ifrs-full_PaymentsForShareIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsForShareIssueCosts", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosuresDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for share issue costs", "negatedLabel": "Share issue costs - cash (Note 17)", "verboseLabel": "Cash placement fees paid" } }, "en": { "role": { "documentation": "The cash outflow for share issue costs." } } }, "auth_ref": [ "r248" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Repayment of lease liability (Note 12)" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r213" ] }, "ngen_PercentageOfReasonablyPossibleChangeInRiskVariable": { "xbrltype": "percentItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "PercentageOfReasonablyPossibleChangeInRiskVariable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of a reasonably possible decrease (increase) in the risk variable.", "label": "Percentage Of Reasonably Possible Change In Risk Variable", "terseLabel": "Depreciation or appreciation of the risk variable" } } }, "auth_ref": [] }, "ngen_PreclinicalDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "PreclinicalDevelopmentExpenseMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesResearchAndDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to preclinical development expense.", "label": "Preclinical Development Expense [Member]", "terseLabel": "Preclinical development" } } }, "auth_ref": [] }, "ngen_PrepaidLicensingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "PrepaidLicensingFees", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails": { "parentTag": "ngen_PrepaymentsDepositsAndOtherCurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for licensing fees that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Licensing Fees", "terseLabel": "Licensing fees" } } }, "auth_ref": [] }, "ngen_PrepaidListingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "PrepaidListingFees", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails": { "parentTag": "ngen_PrepaymentsDepositsAndOtherCurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for listing fees that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Listing Fees", "terseLabel": "Prepaid listing fees" } } }, "auth_ref": [] }, "ngen_PrepaidManufacturingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "PrepaidManufacturingCosts", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails": { "parentTag": "ngen_PrepaymentsDepositsAndOtherCurrentAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The prepaid costs incurred in the production of goods for sale.", "label": "Prepaid Manufacturing Costs", "terseLabel": "Prepaid manufacturing" } } }, "auth_ref": [] }, "ngen_PrepaidMembershipFees": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "PrepaidMembershipFees", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails": { "parentTag": "ngen_PrepaymentsDepositsAndOtherCurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for membership fees that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Membership Fees", "terseLabel": "Prepaid membership fees" } } }, "auth_ref": [] }, "ngen_PrepaidRentAndRelatedDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "PrepaidRentAndRelatedDeposits", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails": { "parentTag": "ngen_PrepaymentsDepositsAndOtherCurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for rent and related expenses that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Rent And Related Deposits", "terseLabel": "Prepaid rent and related deposits" } } }, "auth_ref": [] }, "ngen_PrepaidSoftware": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "PrepaidSoftware", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails": { "parentTag": "ngen_PrepaymentsDepositsAndOtherCurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for software that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Software", "terseLabel": "Prepaid software" } } }, "auth_ref": [] }, "ngen_PrepaymentsDepositsAndOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "PrepaymentsDepositsAndOtherCurrentAssets", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 }, "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePrepaidsDepositsAndOtherCurrentAssetsDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "The amount of prepayments, deposits and other current assets.", "label": "Prepayments, Deposits And Other Current Assets", "terseLabel": "Prepaids, deposits, and other current assets (Note 9)", "totalLabel": "Prepaids, deposits, and other current assets" } } }, "auth_ref": [] }, "ifrs-full_PreviouslyStatedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PreviouslyStatedMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfCashFlowsDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Previously stated [member]", "terseLabel": "As Previously Stated" } }, "en": { "role": { "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)." } } }, "auth_ref": [ "r46", "r47", "r48", "r128", "r129", "r130", "r183" ] }, "ifrs-full_ProceedsFromExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfOptions", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of options", "terseLabel": "Cash proceeds from exercise of stock options" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of options." } } }, "auth_ref": [ "r248" ] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants", "terseLabel": "Cash proceeds from exercise of warrants" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r248" ] }, "ngen_ProceedsFromExerciseOfWarrantsAndOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ProceedsFromExerciseOfWarrantsAndOptions", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the exercise of warrants and options.", "label": "Proceeds From Exercise Of Warrants And Options", "terseLabel": "Warrant and option exercises (Note 18)" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCommitmentDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from government grants, classified as financing activities", "terseLabel": "Grants received" } }, "en": { "role": { "documentation": "The cash inflow from government grants, classified as financing activities. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r246" ] }, "ngen_ProceedsFromIssuanceOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ProceedsFromIssuanceOfUnits", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuing of units.", "label": "Proceeds From Issuance Of Units", "terseLabel": "Gross proceeds from units" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureBasisOfPresentationDetails", "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosuresDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Gross proceeds from issuance of common shares (Note 16, 17)", "verboseLabel": "Aggregate gross proceeds" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r212" ] }, "ngen_ProceedsFromIssuingSharesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ProceedsFromIssuingSharesNet", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosuresDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuing shares, net of share issuance costs.", "label": "Proceeds From Issuing Shares, Net", "terseLabel": "Aggregate net proceeds", "verboseLabel": "Net proceeds" } } }, "auth_ref": [] }, "ngen_ProceedsFromNetInvestmentInLease": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ProceedsFromNetInvestmentInLease", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from net investments in lease.", "label": "Proceeds From Net Investment In Lease", "terseLabel": "Payments received from net investment in lease (Note 12)" } } }, "auth_ref": [] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosuresDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Professional fees expense", "terseLabel": "Professional fees incurred" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfCashFlowsDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfCashFlows", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Net loss for the period", "totalLabel": "Net loss", "verboseLabel": "Loss and comprehensive loss" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r51", "r53", "r109", "r110", "r150", "r159", "r184", "r206", "r215", "r222" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePropertyAndEquipmentDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment", "periodEndLabel": "Balance at end", "periodStartLabel": "Balance at beginning", "terseLabel": "Property and equipment (Note 11, 12)" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r12", "r142", "r191" ] }, "ngen_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "PublicOfferingMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureBasisOfPresentationDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for public offering of securities by a company to investors, including the issuance of shares or other securities to raise capital.", "label": "Public Offering [Member]", "terseLabel": "Public offering" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsFairValueOfOptionsGrantedDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r42", "r68", "r78", "r93", "r124", "r218", "r220", "r253" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsFairValueOfOptionsGrantedDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r42", "r68", "r78", "r93", "r124", "r218", "r220", "r253" ] }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r93" ] }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangesOfExercisePricesForOutstandingShareOptionsDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Range [domain]]" } } }, "auth_ref": [ "r93" ] }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIntangibleAssetDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in intangible assets other than goodwill [abstract]", "terseLabel": "Changes in intangible asset" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in property, plant and equipment [abstract]", "terseLabel": "Changes in the carrying amounts of equipment" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInRightofuseAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfChangesInRightofuseAssetsAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in right-of-use assets [abstract]", "terseLabel": "Right-of-Use Asset" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfNumberOfSharesOutstandingAbstract", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalScheduleOfNumberOfSharesOutstandingAndWeightedAverageNumberOfSharesDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of number of shares outstanding [abstract]", "terseLabel": "Reconciliation of number of shares outstanding" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesResearchAndDevelopmentExpenseDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "terseLabel": "Research and development expenses", "verboseLabel": "Research and development (Note 20)" } } }, "auth_ref": [ "r35", "r156" ] }, "ngen_ResearchAndDevelopmentTaxCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ResearchAndDevelopmentTaxCreditMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails", "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for research and development tax credit.", "label": "Research And Development Tax Credit [Member]", "terseLabel": "US R&D tax credit" } } }, "auth_ref": [] }, "ngen_ResearchAndDevelopmentUnderSection174Member": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ResearchAndDevelopmentUnderSection174Member", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails", "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits attributable to research and development expenses under Section 174 of Internal Revenue Code.", "label": "Research and Development Under Section 174 [Member]", "terseLabel": "R&D under Section 174" } } }, "auth_ref": [] }, "ifrs-full_ReserveOfSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfSharebasedPayments", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Reserve of share-based payments", "terseLabel": "Reserves (Note 18)" } }, "en": { "role": { "documentation": "A component of equity resulting from share-based payments." } } }, "auth_ref": [ "r262" ] }, "ifrs-full_ReserveOfSharebasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfSharebasedPaymentsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Reserve of share-based payments [member]", "terseLabel": "Reserves" } }, "en": { "role": { "documentation": "This member stands for a component of equity resulting from share-based payments." } } }, "auth_ref": [ "r229" ] }, "ifrs-full_RestatedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestatedMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfCashFlowsDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Currently stated [member]" } }, "en": { "role": { "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used." } } }, "auth_ref": [ "r46", "r47", "r48", "r77", "r128", "r129", "r130", "r183", "r259" ] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Deficit" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r228", "r230", "r231" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained earnings [member]", "terseLabel": "Deficit" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r186", "r229" ] }, "ngen_RetentionSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "RetentionSecuritiesMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for retention securities.", "label": "Retention Securities [Member]", "terseLabel": "Retention Securities" } } }, "auth_ref": [] }, "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfCashFlowsDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Retrospective application and retrospective restatement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r46", "r47", "r48", "r128", "r129", "r130", "r183" ] }, "ngen_ReversalOfShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ReversalOfShareBasedCompensationExpense", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of reversal of share based compensation expense recognized during the period.", "label": "Reversal Of Share Based Compensation Expense", "terseLabel": "Reversal of stock-based compensation expense" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNetInvestmentInLeaseAndLeaseLiabilityChangesInCarryingAmountsDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets", "periodEndLabel": "Balance at end", "periodStartLabel": "Balance at beginning" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r69", "r73", "r119" ] }, "ngen_SalariesAndBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "SalariesAndBenefitsMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesGeneralAndAdministrationExpenseDetails", "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesResearchAndDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to salaries and benefits.", "label": "Salaries and Benefits [Member]", "terseLabel": "Salaries and benefits" } } }, "auth_ref": [] }, "ngen_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsRestatementTable": { "xbrltype": "stringItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsRestatementTable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfCashFlowsDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfChangesInShareholdersEquityDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about prior period adjustment to correct error in previously issued financial statement. Includes, but is not limited to, effect of correction on financial statement line item, affected per-share amount, cumulative effect of change on retained earnings and other appropriate component of equity or net assets in statement of financial position, and effect of prior period adjustment on net income of each prior period presented.", "label": "Schedule of Error Corrections and Prior Period Adjustments Restatement [Table]" } } }, "auth_ref": [] }, "ngen_ScheduleOfTradeAndOtherCurrentPayablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ScheduleOfTradeAndOtherCurrentPayablesTableTextBlock", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information relating to trade and other current payables.", "label": "Schedule Of Trade And Other Current Payables [Table Text Block]", "terseLabel": "Schedule of accounts payable and accrued liabilities" } } }, "auth_ref": [] }, "ngen_ScientificResearchAndExperimentalDevelopmentExpenditureMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ScientificResearchAndExperimentalDevelopmentExpenditureMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails", "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits attributable to scientific research and experimental development expenditures.", "label": "Scientific Research and Experimental Development Expenditure [Member]", "terseLabel": "Scientific research and experimental development expenditures", "verboseLabel": "SRED pool" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r233" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r235" ] }, "ifrs-full_SettlementsFairValueMeasurementLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SettlementsFairValueMeasurementLiabilities", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfReconciliationOfChangeInFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Settlements, fair value measurement, liabilities", "negatedLabel": "Derecognition of warrant derivative" } }, "en": { "role": { "documentation": "The decrease in the fair value measurement of liabilities resulting from settlements. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r65" ] }, "ngen_ShareIssueCostsAndFinancingFeeMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "ShareIssueCostsAndFinancingFeeMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails", "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits attributable to share issue costs and financing fee.", "label": "Share Issue Costs and Financing Fee [Member]", "terseLabel": "Share issue costs and financing fee" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Share issue related cost", "terseLabel": "Share issue related cost" } } }, "auth_ref": [ "r256" ] }, "ifrs-full_ShorttermEmployeeBenefitsAccruals": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermEmployeeBenefitsAccruals", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term employee benefits accruals", "terseLabel": "Employee related costs" } }, "en": { "role": { "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]" } } }, "auth_ref": [ "r263" ] }, "ngen_SignificantObservableInputLiabilities": { "xbrltype": "decimalItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "SignificantObservableInputLiabilities", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeScheduleOfAssumptionForEstimatedFairValueOfWarrantDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The value of significant observable input used in the measurement of the fair value of liabilities.", "label": "Significant Observable Input, Liabilities", "terseLabel": "Significant observable inputs" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Changes in Shareholders' Equity" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]", "terseLabel": "Consolidated Statements of Changes in Shareholders' Equity (Deficit)" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r186" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Financial Position" } } }, "auth_ref": [] }, "ngen_StockBasedCompensationMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "StockBasedCompensationMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesGeneralAndAdministrationExpenseDetails", "http://NervgenPharmaCorp.com/role/DisclosureNatureOfExpensesResearchAndDevelopmentExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to stock-based compensation.", "label": "Stock-Based Compensation [Member]", "terseLabel": "Stock-based compensation" } } }, "auth_ref": [] }, "ngen_StockProceedsAllocatedToEquityComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "StockProceedsAllocatedToEquityComponent", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of proceeds from stock issuance allocated to equity component.", "label": "Stock Proceeds Allocated to Equity Component", "terseLabel": "Share capital" } } }, "auth_ref": [] }, "ngen_StockProceedsAllocatedToLiabilityComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "StockProceedsAllocatedToLiabilityComponent", "crdr": "credit", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of proceeds from stock issuance allocated to liability component.", "label": "Stock Proceeds Allocated to Liability Component", "terseLabel": "Warrant liability" } } }, "auth_ref": [] }, "ngen_TaxEffectFromChangeInStatutoryForeignTaxRateForeignExchangeRates": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "TaxEffectFromChangeInStatutoryForeignTaxRateForeignExchangeRates", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes statutory rate, foreign rate and foreign exchange rates.", "label": "Tax Effect From Change in Statutory, Foreign Tax Rate, Foreign Exchange Rates", "terseLabel": "Change in statutory tax, foreign tax, foreign exchange rates" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectFromChangeInTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxEffectFromChangeInTaxRate", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Tax effect from change in tax rate", "terseLabel": "Change in statutory tax rate" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]" } } }, "auth_ref": [ "r3", "r134" ] }, "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)", "terseLabel": "Permanent differences" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]" } } }, "auth_ref": [ "r3", "r134" ] }, "ngen_TaxEffectOfShareIssueCostsAndFinancingFee": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "TaxEffectOfShareIssueCostsAndFinancingFee", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to share issuance costs and financing fee.", "label": "Tax Effect of Share Issue Costs and Financing Fee", "terseLabel": "Share issue costs and financing fee" } } }, "auth_ref": [] }, "ngen_TaxEffectOfUnrecognizedDeductibleTemporaryDifferences": { "xbrltype": "monetaryItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "TaxEffectOfUnrecognizedDeductibleTemporaryDifferences", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to unrecognized deductible temporary differences.", "label": "Tax Effect of Unrecognized Deductible Temporary Differences", "terseLabel": "Change in unrecognized deductible temporary differences" } } }, "auth_ref": [] }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxExpenseIncomeAtApplicableTaxRate", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesWithReportedTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Tax expense (income) at applicable tax rate", "terseLabel": "Expected income tax (recovery)" } }, "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r3", "r134" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails", "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails" ], "lang": { "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r7", "r138" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails", "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails" ], "lang": { "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [domain]" } }, "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r7", "r138" ] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsFairValueOfOptionsGrantedDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Top of range [member]", "terseLabel": "Maximum" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r42", "r68", "r78", "r93", "r124", "r218", "r220", "r253" ] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails": { "parentTag": "ifrs-full_CurrentAssetsLiabilities", "weight": -1.0, "order": 1.0 }, "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails", "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails", "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Trade and other current payables", "negatedLabel": "Accounts payable and accrued liabilities", "terseLabel": "Accounts payable and accrued liabilities (Note 14, 15)", "totalLabel": "Total accounts payable and accrued liabilities" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r195" ] }, "ifrs-full_TradeAndOtherCurrentPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesAbstract", "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 }, "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails": { "parentTag": "ifrs-full_CurrentAssetsLiabilities", "weight": 1.0, "order": 3.0 }, "http://NervgenPharmaCorp.com/role/DisclosureReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails", "http://NervgenPharmaCorp.com/role/DisclosureReceivablesDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Receivables (Note 10)", "totalLabel": "Receivables", "verboseLabel": "Receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r180", "r193", "r201" ] }, "ifrs-full_TradeAndOtherReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Receivables" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://NervgenPharmaCorp.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementCurrencyRiskDetails", "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r19", "r79", "r80", "r81", "r83", "r99", "r101", "r102", "r146" ] }, "ifrs-full_TypesOfRisksDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementCurrencyRiskDetails", "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementScheduleOfCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "label": "Types of risks [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r19", "r79", "r80", "r81", "r83", "r99", "r101", "r102", "r146" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r94", "r167" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r94", "r167" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "US", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails", "http://NervgenPharmaCorp.com/role/DisclosureSegmentReportingDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "USA" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "USD", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureFinancialRiskManagementCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "label": "United States of America, Dollars", "terseLabel": "U.S. dollar" } } }, "auth_ref": [] }, "ngen_UnitsIssuedDuringPeriodUnitsNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "UnitsIssuedDuringPeriodUnitsNewIssues", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails", "http://NervgenPharmaCorp.com/role/DisclosureWarrantDerivativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of new units issued during the period.", "label": "Units Issued During Period, Units, New Issues", "terseLabel": "Number of units issued" } } }, "auth_ref": [] }, "ngen_UnpaidAccruedBonusAndVacationMember": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "UnpaidAccruedBonusAndVacationMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits attributable to unpaid accrued bonus and vacation.", "label": "Unpaid Accrued Bonus and Vacation [Member]", "terseLabel": "Unpaid accrued bonus and vacation" } } }, "auth_ref": [] }, "ifrs-full_UnrealisedForeignExchangeGainsLossesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnrealisedForeignExchangeGainsLossesMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Unrealised foreign exchange gains (losses) [member]", "terseLabel": "Foreign exchange" } }, "en": { "role": { "documentation": "This member stands for gains (losses) resulting from changes in foreign exchange rates which have not yet been realised." } } }, "auth_ref": [ "r243" ] }, "ifrs-full_UnusedTaxLossesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnusedTaxLossesMember", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesDeferredIncomeTaxDetails", "http://NervgenPharmaCorp.com/role/DisclosureIncomeTaxesTemporaryDifferencesUnusedTaxCreditsAndUnusedTaxLossesNotIncludedInStatementsOfFinancialPositionDetails" ], "lang": { "en-us": { "role": { "label": "Unused tax losses [member]", "terseLabel": "Non-capital losses available for future periods" } }, "en": { "role": { "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit." } } }, "auth_ref": [ "r7", "r138" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureIntangibleAssetDetails" ], "lang": { "en-us": { "role": { "label": "Useful life measured as period of time, intangible assets other than goodwill", "terseLabel": "Useful life of license patent" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r31", "r152" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureMaterialAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Useful life measured as period of time, property, plant and equipment", "terseLabel": "Expected life of the assets" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r9", "r139" ] }, "ngen_WarrantsExercisePrice2.35Member": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "WarrantsExercisePrice2.35Member", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for warrants with exercise price of $2.35.", "label": "Warrants, Exercise Price 2.35 [Member]", "terseLabel": "2.35" } } }, "auth_ref": [] }, "ngen_WarrantsExercisePrice2.44Member": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "WarrantsExercisePrice2.44Member", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for warrants with exercise price of $2.44.", "label": "Warrants, Exercise Price 2.44 [Member]", "terseLabel": "2.44" } } }, "auth_ref": [] }, "ngen_WarrantsExercisePrice3.00Member": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "WarrantsExercisePrice3.00Member", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for warrants with exercise price of $3.00.", "label": "Warrants, Exercise Price 3.00 [Member]", "terseLabel": "3.00" } } }, "auth_ref": [] }, "ngen_WarrantsExercisePrice3.63Member": { "xbrltype": "domainItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "WarrantsExercisePrice3.63Member", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for warrants with exercise price of $3.63.", "label": "Warrants, Exercise Price 3.63 [Member]", "terseLabel": "3.63 (US 2.65)" } } }, "auth_ref": [] }, "ngen_WarrantsExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "WarrantsExercisedDuringPeriod", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised during the period.", "label": "Warrants Exercised During Period", "negatedLabel": "Number of shares issuable under warrants, Exercised" } } }, "auth_ref": [] }, "ngen_WarrantsGrantedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "WarrantsGrantedDuringPeriod", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureKeyManagementPersonnelAdditionalInformationDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants granted during the period.", "label": "Warrants Granted During Period", "terseLabel": "Number of shares issuable under warrants, Granted", "verboseLabel": "Warrants owned" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement", "terseLabel": "Exercise price" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r252" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement", "terseLabel": "Weighted average exercise Price ($)" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r90", "r165" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options exercised in share-based payment arrangement", "terseLabel": "Weighted average exercise price, Exercised" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r88", "r163" ] }, "ngen_WeightedAverageExercisePriceOfShareOptionsForfeitedOrExpiredInShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedOrExpiredInShareBasedPaymentArrangement", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The weighted average exercise price of share options forfeited or expired in a share-based payment arrangement.", "label": "Weighted Average Exercise Price Of Share Options Forfeited or Expired In Share-based Payment Arrangement", "terseLabel": "Weighted average exercise price, Forfeited/Expired" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options granted in share-based payment arrangement", "terseLabel": "Weighted average exercise price, Granted" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r86", "r161" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails", "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement", "periodEndLabel": "Weighted average exercise price, ending balance", "periodStartLabel": "Weighted average exercise price, beginning balance", "terseLabel": "Weighted average exercise Price ($)" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r85", "r89", "r160", "r164" ] }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life of outstanding share options", "terseLabel": "Weighted average remaining contractual life (Years)" } }, "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r93" ] }, "ngen_WeightedAverageRemainingContractualLifeOfShareOptionsExercisable": { "xbrltype": "durationItemType", "nsuri": "http://NervgenPharmaCorp.com/20251231", "localname": "WeightedAverageRemainingContractualLifeOfShareOptionsExercisable", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureStockOptionsRetentionSecuritiesAndWarrantsStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The weighted average remaining contractual life of share options exercisable in a share-based payment arrangement.", "label": "Weighted Average Remaining Contractual Life Of Share Options Exercisable", "terseLabel": "Weighted average remaining contractual life (Years)" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageSharePrice2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageSharePrice2019", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureCapitalDisclosuresDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalDetails", "http://NervgenPharmaCorp.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Weighted average price" } }, "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r92" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://NervgenPharmaCorp.com/role/DisclosureRestatementOfPriorPeriodFinancialStatementsConsolidatedStatementsOfLossAndComprehensiveLossDetails", "http://NervgenPharmaCorp.com/role/DisclosureShareCapitalScheduleOfNumberOfSharesOutstandingAndWeightedAverageNumberOfSharesDetails", "http://NervgenPharmaCorp.com/role/StatementConsolidatedStatementsOfLossAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average Common Shares outstanding, Basic (in shares) (Note 17)" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r28" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "20", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "A19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_46&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "29", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_29_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "49", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_49_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "49", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_49_c&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_125&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_h&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_a&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_b&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_b&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "170", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_170&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "176", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "178", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_178_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "179", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_179_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "186", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_186_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "186", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_186_c&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_e&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_c&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "216", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_216_a&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "223", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_f&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_a&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "34", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_34_a&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "43", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "88", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_88_a&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B13", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_b&doctype=Standard", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "134", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_134&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "136", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_136&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_h&doctype=Standard", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_g&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE60", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE60&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG40B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "191", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_191_f&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r233": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r234": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r237": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r238": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r239": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r240": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r241": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "20", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14&doctype=Standard", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_20_d&doctype=Standard", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }